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Introduction: Plasmablastic lymphoma (PBL) is a rare, aggressive, AIDS-associated non-Hodgkin 
lymphoma. The pathogenesis of PBL is incompletely understood, however association with the 
Epstein-Barr virus (EBV) and the MYC gene, have been identified as important pathogenic 
mechanisms.  
Aims and objectives: To characterise the EBV latency in a cohort of patients diagnosed with PBL 
at Groote Schuur Hospital (GSH), by means of immunohistochemistry. To determine MYC gene 
aberrations using fluorescent in situ hybridisation (FISH). 
Materials and methods: The cohort comprised PBL cases diagnosed from 2005-2017. EBER ISH 
was used to confirm EBV infection. Manual immunohistochemistry using three monoclonal 
antibodies for EBV latent proteins, (EBNA1, EBNA2 and LMP1) was used to determine the 
latency type. Manual MYC FISH was performed on all PBL cases using a dual colour break apart 
rearrangement probe.  
Results: Forty-nine cases of PBL were included in this study. Forty-one cases were positive for 
EBER ISH. Thirty-seven (78.7%) cases showed HIV/EBV coinfection. Latency 0 was observed in 
29 (70.7%) cases, latency 1 in 8 (19.5%) and latency 2 in 4 (9.8%) cases. MYC FISH was 
performed on all 49 PBL cases, of which 30 (61.2%) yielded a result.  MYC was intact in 11 
(36.7%), translocated in 8 (26.7%) and 11 (36.7 %) cases showed copy number variations.  
Conclusion: Our research demonstrated 37 (90.2%) of the EBV positive PBL cases showed a 
restricted latency pattern of 0 or 1. Furthermore we found that MYC gene aberrations 
consisting of translocations and copy number variations occurred in 19 cases (63.3%) , with 
copy number variations being higher than cited in current literature. Our study is also the first 
to investigate PBL EBV latency in SA. An uncommon finding was the existence of MYC gene 












1.1 Plasmablastic lymphoma epidemiology and clinical features   
Plasmablastic lymphoma (PBL) is a rare, aggressive B-cell, non-Hodgkin’s lymphoma (NHL) 
commonly associated with the Human Immunodeficiency Virus (HIV) (Castillo et al., 2015, 
Campo et al., 2017). It was originally described as presenting in the jaw and oral mucosa of HIV 
positive patients by Delecluse et al in 1997 (Delecluse et al., 1997). Based on its morphological 
and clinical features, PBL was classified as a distinct sub-type of diffuse large B-cell lymphoma 
(DLBCL) (Elyamany et al., 2015a), but in the 2008 edition of the World Health Organisation 
(WHO) classification of “Tumours of Haematopoietic and Lymphoid Tissues”, PBL was 
reclassified as a distinct separate entity from DLBCL (Bibas and Castillo, 2014).  
 
PBL makes up approximately 2.6% of all HIV related lymphomas (Castillo et al., 2015, Chetty et 
al., 2003) and is  described as either an Acquired Immune Deficiency Syndrome (AIDS) defining 
disease or as an AIDS associated lymphoma.  Despite being associated with HIV/AIDS, PBL also 
presents in immunocompetent, the elderly and patients on iatrogenic immunosuppression 
following organ transplant (Campo et al., 2017, Elyamany et al., 2015a, Bibas and Castillo, 2014, 
Harmon and Smith, 2016, Vaubell et al., 2014). South Africa (SA) has the highest global HIV rate  
(Alli and Meer, 2017, Boy et al., 2015) and according to a 2018 StatsSA report that of the 57.73 
million population, 13.1% are HIV positive. For adults between the ages of 15 and 49, 19% are 
HIV positive (StatsSA, 2018). HIV/AIDS has been associated with an increased risk for the 
development of NHLs, but the proportion and incidence of PBL in SA is relatively unknown. 
There have been some single institute studies and reviews of the effect of HIV, on particularly 
NHL as well as head and neck lymphomas (HNL) that have given a better understanding as to 
effect of this virus in a SA context. The effect of HIV on NHL in a SA perspective is evident based 
on a study in 2015 conducted at the Chris Hani Baragwanath Academic Hospital (CHBAH). This 
retrospective study found an increase in previously rare lymphomas such as PBL. It was also 
found that HIV positive patients presented with more aggressive, high-grade B-cell lymphomas 
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than HIV negative counterparts (Patel et al., 2015). An important observation garnered from 
this study highlighted the effect that lack of access to antiretroviral therapy had on the 
progression and aggression of NHLs such as PBL. Combined anti-retroviral therapy (c-ART) was 
slower to reach certain SA areas than other areas in the rest of the world (Patel et al., 2015). 
Lymphomas of the head and neck (HNL) are the second most frequently reported extranodal 
lymphomas. HNL have shown an increase with the advent of the HIV epidemic, particularly in 
SA. A study of HNL in the Department of Oral Pathology of the University of Witwaterstrand 
(WITS) found a marked increase in high-grade B-cell lymphomas such as PBL in HIV positive 
patients (Alli and Meer, 2017). 
 
PBL shows  a strong male predominance with approximately 70 - 80% of cases occurring in 
men (Castillo et al., 2015).  The median age of presentation in adults who are HIV positive is 
about 39 years and 58 years in HIV negative adults. Paediatric cases are very rare, with the first 
case being described in 2004 by Colomo et al and later by Vaubell et al in a SA context (Vaubell 
et al., 2014, Castillo et al., 2015, Colomo et al., 2004). In the 2017 WHO, PBL may present in 
children with immunodeficiency, particularly HIV associated (Campo et al., 2017). Despite 
originally being diagnosed in the oral cavity of HIV positive patients, PBL may frequently be 
found extra-orally, (Wang et al., 2014). It is primarily an extranodal disease and presents in 
sites such as the gastrointestinal tract, lung, omentum, bone marrow, gall bladder or skin (Bibas 
and Castillo, 2014, Castillo et al., 2015, Castillo et al., 2008, Castillo and Reagan, 2011, Campo 
et al., 2017).  Nodal or primary lymph node disease is rare (Ikpatt et al., 2012), and accounts 
for less than 10%  of PBL cases, but may occur in up to 30% of post-transplant cases (Campo et 
al., 2017).  
 
1.1.1 Prognosis and treatment 
Most patients present with advanced stage disease and due to the aggressive nature of PBL, 
the overall prognosis of patients is very poor.  (Lopez and Abrisqueta, 2018). The median 
overall survival (OS) is  between 8 and 15 months (Castillo et al., 2008). This is however 
dependant on the immune status of the patient,  with HIV positive patients surviving about 10 
months, while with HIV negative patients the overall survival (OS) is about 11 months (Morscio 
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et al., 2014, Lopez and Abrisqueta, 2018). In patients with post-transplant immune 
suppression, the OS decreases to about 7 months. Some studies have suggested that HIV 
positive patients on antiretroviral treatment such as combined antiretroviral therapy (cHART) 
had a better outcome and OS than HIV negative patients with the same lymphoma (Misra et 
al., 2017). This was attributed to the possible involvement of antiretroviral treatment in 
restoring the body’s immunological status  (Lopez and Abrisqueta, 2018, Carroll and Garzino-
Demo, 2015). However, one of the main challenges remains is that cHART is not always 
available to HIV positive patients in Sub-Saharan Africa (SSA) where the incidences of HIV and 
AIDS are at the highest levels in the world (Carbone et al., 2014). PBL is most commonly treated  
with a regimen that includes cyclophosphamide, doxorubicin, vincristine and prednisone or 
etoposide, vincristine and doxorubicin with bolus cyclophosphamide and prednisone (EPOCH) 
(Castillo et al., 2015). In the case of HIV positive PBL, the treatment would involve EPOCH and 
cHART (Castillo et al., 2015).  
 
1.1.2 Morphology 
PBL shows diffuse infiltrates of discohesive uniform large cells, with a prominent starry sky 
appearance. The tumour cells have a high nuclear to cytoplasmic ratio with large vesicular 
nuclei, distinct smooth nuclear membrane, immature chromatin and multiple prominent 
nucleoli. There are frequent mitotic figures present with occasional atypical forms. The 
cytoplasm varies from bright to pale eosinophilic.  Most cells have distinct paranuclear hofs 
(Harmon and Smith, 2016, Swerdlow et al., 2016, Campo et al., 2017) (Figure 1.1A) A 
paranuclear hof is the Golgi apparatus, which in plasma cells demonstrates the areas where 
protein synthesis and immunoglobin production takes place. The morphologic features of PBLs 
may vary slightly depending on the site of disease. PBLs occurring in HIV negative patients, 
lymph nodes or extranodal sites other than the oral cavity, may display a higher degree of 
plasmacytic differentiation. This may be characterised by smaller round eccentric nuclei with 
course chromatin, often described as “clock-faced”. There is also abundant basophilic 
cytoplasm (Harmon and Smith, 2016) (Figure 1.1B). Areas of necrosis, mitotic figures, apoptotic 
bodies and tingible body macrophages may also be present in both variants. Tingible body 
macrophages are not however a diagnostic criterion, as they may be observed in other 
lymphomas as well and are an indicator of the rate of “mopping up” of apoptotic bodies and 
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cell debris. The occurrence of these tingible body macrophages often leads to the description 
of a “starry sky” appearance when viewing under a microscope (Campo et al., 2017). 
 
 
Figure 1.1: Photomicrograph of PBL. A. PBL of oral cavity (H&E x 30) B. PBL with plasmacytic 
differentiation (H&E x30) (Saraceni et al., 2013, Ramnani, 2016) 
 
1.1.3 Immunophenotype 
The immunohistochemical expression pattern of several B-cell and plasma cell markers are 
essential for the diagnosis of PBL. Even though PBL is a B-cell lymphoma, mature B-cell markers 
such as CD19, CD20, CD45 and PAX5 are not expressed. Additionally, B-cell lymphoma 2 (BCL2) 
and B-cell lymphoma 6 (BCL6) proteins, which are B-cell markers linked to germinal centre cell 
origin, are also expected to be negative. Plasmacytic differentiation markers such as  MUM1, 
CD38, CD138 and VS38C are however expressed (Fernandez-Alvarez et al., 2016). Other 
markers such as CD79a are positive in 40% of PBL cases with CD56 and CD10 expressed in 25% 
and 20% of the cases respectively. EMA and CD30 are also frequently expressed. Ki67, which 
is a proliferation index is often very high (~80-90%).  
 
Differential markers such as LANA-1, which is a latency protein expressed by human 
herpesvirus (HHV-8), is expected to be negative in order to exclude the plasmablastic variant 
of HHV-8 positive multicentric Castleman disease (MCD). MCD is however also EBV negative, 
but may be HIV positive or negative (Said et al., 2017).  Another differential marker is ALK 
6 
 
(anaplastic lymphoma kinase), which is used to excluded ALK-positive large B-cell lymphoma 
(ALK-positive LBCL) (Dupin et al., 2000).  
 
1.1.4 Diagnostic challenges 
Based on its immunohistochemical and morphological profile, the diagnosis of PBL  may be 
sometimes be difficult , as it shares features which overlap with other B-cell lymphomas with 
plasmablastic morphology (Castillo et al., 2015) such as  plasmablastic plasma cell myeloma 
(PCM) , primary effusion lymphoma (PEL) and ALK-positive LBCL.  In the setting of HIV infection, 
both PCM and PBL can be associated with EBV, thus making their distinction challenging. The 
morphological features of PCM and PBL are almost identical, and other diagnostic aids such as 
radiographic and clinical presentation need to be considered. For example, PCM shows diffuse 
bone/bone marrow involvement while PBL is largely associated with EBV and HIV infections 
(Bibas and Castillo, 2014, Harmon and Smith, 2016, Castillo et al., 2015). Another hallmark 
clinicopathological characteristic is that PCM exhibits monoclonal para-proteinemia, which is 
not present in PBL (Taddesse-Heath et al., 2010). For PEL, the clinical history involves the 
presence of cavity serous effusion. However, this may be complicated though in the rare cases 
where PEL presents as solid tumour masses (extracavity PEL). Extracavity PEL, which may 
display immunoblastic or plasmablastic morphology is also associated with HIV infection 
(Harmon and Smith, 2016). The immunophenotypes are also very similar, but  extracavity PEL 
is positive for  HHV-8 (Harmon and Smith, 2016) while PBL is not.  
 
ALK-positive LBCL are rare and often exhibit a diffuse pattern with immunoblastic or 
plasmablastic cells. Immunohistochemically they are also negative for CD20 and positive for 
plasma cell markers such as CD38, CD138 and VS38C.  The distinguishing factor is that PBL is 
not positive for the ALK marker, which is positive in cases of ALK-positive LBCL (Harmon and 
Smith, 2016, Katchi and Liu, 2017, Castillo et al., 2015, Pan et al., 2017). MCD is often associated 
with the development of other B-cell lymphomas. HHV-8 positive DLBCL may arise in 
association with HHV-8 positive MCD. HHV-8 infection has been associated with some, but not 
all cases of MCD (Bower et al., 2011) where the morphology is characterised by the presence 
of plasmablasts, predominantly in the mantle zones. As a result of the cells morphologically 
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resembling plasmablasts, the diagnosis of PBL should be excluded. HHV-8 positive DLBCL is 
however usually associated with HIV positivity. Additionally, the plasmablasts may stain CD20 
-/+, CD79a -/+, MUM1 +, CD138 - and CD38-/+. However, EBER for EBV detection is negative 
(Dupin et al., 2000, Wang et al., 2016) .    
 
1.1.5 Pathogenesis  
The pathogenesis of PBL is incompletely understood, but the V-Myc Avian Myelocytomatosis 
Viral Oncogene Homolog (MYC) gene, Epstein-bar virus and HIV may be significant role players 
in the development of PBL. These role players all have oncogenic potential and can influence 
the body’s immune response and the development of various lymphomas.  In HIV associated 
lymphomas such as PBL, the virus is thought to impair the body’s immune system and normal 
B-cell function. This may allow uncontrolled  B-cell proliferation and possible secondary 
oncogenic viral infection  by viruses such as EBV (Gloghini et al., 2013), which together with 
MYC rearrangements are observed as the main pathogenic route in PBL (Boy et al., 2011). 
Particularly in HIV associated PBL, the cell of origin is thought to be derived from post-germinal 
centre B-cells which have undergone antigen stimulation and are in the process of developing 
into plasma cells (Castillo and Reagan, 2011).  
 
1.2 Lymph nodes, germinal centre process and plasmablast formation  
Lymph nodes show slight variation in their structure depending on their anatomical site. Basic 
structures include lymphoid follicles, paracortex, medullary cords and sinuses. Lymphoid 
follicles are regions responsible for T-cell dependant immune responses and are made up of 
primary and secondary follicles. These are the structures within a lymph node where antibody 
diversity and isotype switching occurs. Primary follicles contain B-cells and follicular dendritic 
cells (Ashton-Key et al., 2016).  
 
Germinal centres (GC) form within secondary lymphoid organs including the spleen, tonsils and 
lymph nodes (Klein and Dalla-Favera, 2008). Secondary follicles show the presences of 
germinal centres which contain two distinct compartments or zones.  These are the dark zone 
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(DZ) and the light zone (LZ) (Figure 1.2) (Victora, 2014, Suan et al., 2017). In the dark zones one 
finds large rapidly dividing centroblasts (activated B-cells) while centrocytes, which are post 
proliferation B-cells with cleaved nuclei, are found in the light zone.  The germinal centre is 
surrounded by the mantle zone (Ashton-Key et al., 2016, Castillo et al., 2015).  
 
Figure 1.2: Diagram of germinal centre reaction, showing site of somatic hypermutation and 
class-switch recombination. Adapted from Klein and Dalla-Favera, 2008 (Klein and Dalla-
Favera, 2008). 
The formation of germinal centres is transient and begins with the acquisition of antigen by 
the resting B-cells (Calado et al., 2012, Scheller et al., 2009, Mesin et al., 2016). These B-cells 
move to the T-cell rich area known as the T-cell zone, where they receive stimulatory signals 
from the CD4+ helper T cells. This triggers a period of intense proliferation (Mesin et al., 2016). 
The proliferating B-cell’s immunoglobulin genes are altered by means of somatic 
hypermutation and class switching  (Scheller et al., 2009, Sampath et al., 2019, Dong et al., 
2005). Plasmablasts are circulating, short lived, antibody secreting differentiated B-cells. Their 
formation is associated with changes in cellular morphology and gene expression. The 
expression of immunoglobulin heavy chain (IgH), immunoglobulin kappa light chain (IgK) and 
9 
 
immunoglobulin lambda light chain (IgL) is greatly increased in plasmablasts, which leads to an 
increased secretion of immunoglobulin proteins (Minnich et al., 2016). 
 
Activation-induced cytidine deaminase (AID), which may act directly on DNA, drives somatic 
hypermutation of the immunoglobulin genes, class switch recombination and proliferation in 
the dark zone (DZ) of the germinal centre (Klein and Dalla-Favera, 2008, De Silva and Klein, 
2015). This leads to the production of B-cells that express B-cell receptors (BCR) with an affinity 
for initiating antigen. These B-cells leave the DZ and enter the LZ where they are tested by the 
follicular dendritic cells for their ability to engage antigen (Suan et al., 2017). B-cells may also 
re-enter the DZ and begin additional cycles of SHM. This is known as cyclic re-entry (Figure 1.2). 
B-cells may then be selected to produce long lived plasma cells or memory B-cells. Non-
selected B-cells are eliminated by means of apoptosis (Dominguez-Sola et al., 2012, Suan et al., 
2017). B-cell lymphoma 6 (BCL6) is the master transcriptional regulator and together with B- 
lymphocyte induced maturation protein (BLIMP) are responsible for both plasma cell and 
memory B-cell differentiation in the germinal centre (Klein and Dalla-Favera, 2008, De Silva 
and Klein, 2015).  
 
1.2.1 AID mode of action in SHM and CSR  
To create antibody diversity in B-cells, immunoglobulin (IG) genes need to undergo several 
regulated alterations or controlled mutations. This IG remodelling occurs during the GC 
process and is essential for the humoral immunity response (Smit et al., 2003). In the GC  DZ, 
AID is essential for SHM and CSR in the B-cells (Scheller et al., 2009). SHM is the mutation that 
occurs in the variable regions of the immunoglobulin genes to create greater antigen affinity. 
Class switching, also known isotype switching, is a mechanism that changes the B-cells 
production of immunoglobulin. AID deaminates cytosine to produce uracil in DNA. Mismatches 
that occur may be repaired by mismatch repair genes but may also be processed to produce 
double-stranded breaks that lead to class switch recombination or translocations. The 
translocations that may occur during SHM and CSR can be prevented or repaired by the 
activation of damage signalling proteins such as P53 (McBride et al., 2006). Most non-Hodgkin 
lymphomas (NHL) are of B-cell origin and many exhibit GC or post GC phenotype. Many B-cell 
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related NHL show IG gene related chromosomal translocations which would indicate a 
likelihood of DNA diversification mistakes in the GC, particularly during SHM and CSR (Smit et 
al., 2003, Ramiro et al., 2006). Chromosomal translocations associated with GC related non-
Hodgkin lymphoma, show that the most frequent oncogenic translocation involves MYC and 
IgH created by AID. This occurs during CSR and SHM (Smit et al., 2003). 
 
1.3 MYC gene function and regulation 
The V-Myc Avian Myelocytomatosis Viral Oncogene Homolog (MYC) gene located on 
chromosome 8q24 is part of a gene family that comprises N-MYC, L-MYC and S-MYC. All of 
these MYC genes may code for MYC proteins (Tansey, 2014). MYC is a nuclear phosphoprotein 
which functions as a transcription factor and has both gene activating and gene repressing 
capabilities. MYC forms a heterodimer with another transcription factor, Myc-associated factor 
X (MAX) and regulates between 10-15% of all genes within the human genome. MYC has 
diverse biologic activities which include cell growth promotion and gene activation. These 
activated genes may function by increasing cellular metabolism, mitochondrial biogenesis, and 
biosynthesis of nucleic acids, ribosomes, and various proteins. MYC also functions as an 
important mediator of cell cycle progression, and the activation of proliferative genes that 
could encode for proteins such as cyclin D1 (CCND1) and inhibiting antiproliferative proteins 
such as cyclin-dependent kinase inhibitors. In so doing, MYC can drive the cell from the G0/G1 
phase to the S phase of the cell cycle. MYC also plays a role in apoptosis, but the precise 
mechanism is unknown. MYC is however known to stabilise P53, which is a proapoptotic 
protein and tumour suppressor. MYC is therefore indirectly involved in inhibiting the 
antiapoptotic proteins BCLXL and BCL2. This in turn may induce the expression of BIM, which 
is a proapoptotic protein involved in the stimulation of cytochrome c release from 




Figure 1.3: Role of the MYC gene and protein expression in normal and abnormal cell function. 
Adapted from Reisfeld, 2015 (Reisfeld, 2015). 
 
In addition,  MYC can amplify some of the transcribed genes within a cell (Ott et al., 2013). The 
primary function of normally regulated MYC is in cellular metabolism and growth regulation 
control. MYC expression and function are tightly regulated by mitogenic signals. MYC mRNA 
expression, present in normal cells has a very short half-life in the absence of positive 
regulatory signals. If these regulatory signals are absent, MYC protein levels become low, and 
provide no proliferative drive (Miller et al., 2012). MYC expression activates cell death 
pathways and affects apoptosis when inducing rapid DNA replication, which may lead to 
potential DNA damage. This would elicit the activation of TP53, which is a tumour protein gene 
coding for P53 (Ott et al., 2013). The P53 protein is a tumour repair protein which attempts to 
repair potentially damaged DNA from rapid replication. Failing that, P53 prevents the cell from 
dividing, thereby inducing apoptosis. MYC also encodes for a transcription factor that 
accelerates cell metabolism, proliferation and cell growth (Lynnhtun et al., 2014, Haikala et al., 
2017). In normal cells, MYC coordinates acquisition of nutrients to produce ATP, which is a key 
component in cellular metabolism. MYC protein is important in the regulation of glycolysis by 
means of regulation of glucose metabolism genes (Miller et al., 2012).  MYC plays an important 
role in the formation of the lymphoid follicle and the germinal centre. Naïve B-cells do not 
express MYC, but may do so as a result of antigen stimulation (Karube and Campo, 2015). MYC 
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is expressed in mature B-cells that initiate GC formation but is absent in the highly proliferative 
cells in the GC dark zone. MYC is upregulated in a few B-cells before BCL6 is expressed. BCL6 
expression and binding to the MYC promoter, leads to the repression of MYC. The interplay 
between MYC and BCL6 is associated with the dark zone of the GC and expansion of 
proliferating centroblasts, which are antigen activated B-cells. MYC negative cells in the light 
zone, may exit the germinal centre as memory cells or “immature” plasmablasts. BLIMP1 
expression in these cells and MYC repression may lead to plasma cell differentiation (Ott et al., 
2013). When the oncogenic potential of MYC is unlocked, and it is over expressed, it can drive 
metabolic genes and amplify gene expression in a non-linear way. This distorted gene 
expression leads to silencing of certain cell cycle checkpoints, and the uncontrolled growth 
creates dependence on MYC driven metabolic pathways, such as its effect on ATP production 
and glycolysis (Stine et al., 2015). This abnormal metabolic function also leads to the promotion 
of lipid, nucleotide and protein synthesis by MYC (Haikala et al., 2017). Oncogenic MYC 
expression can induce growth factor dependant cell cycle entry and prevent the cell cycle exit 
(Stine et al., 2015).  
 
1.3.1 MYC and other gene aberrations in PBL 
The oncogenic potential of MYC was first demonstrated in 1985, when it was discovered 
coupled with the immunoglobulin enhancer in mice, resulting in the formation of mature B-
cell neoplasms (Vennstrom et al., 1982, Morton and Sansom, 2013, Nguyen et al., 2017). The 
t(8;14) (q24;q32) translocation involving MYC ( 8q24) and the IGH gene (14q32), is the most 
common genetic aberration observed in PBL, and is observed in about 60% of all PBL cases 
(Valera et al., 2010, Montes-Moreno et al., 2017, Bogusz et al., 2009)   (Figure 1.4). This  led to 
the suggestion that MYC activation plays an important role in PBL pathogenesis, and possible 
over expression of MYC protein (Harmon and Smith, 2016, Montes-Moreno et al., 2017). It is 
also however evident that MYC protein may be over expressed in PBL irrespective of whether 
there were MYC translocations, or any other MYC genetic alterations present. The overall 
survival rate of PBL patients decreases substantially when there are MYC aberrations present.  
(Montes-Moreno et al., 2017, Elyamany et al., 2015b). Besides translocations of the MYC gene, 




Figure 1.4: Diagrammatic representation of the reciprocal translocation 
of MYC gene on chromosome 8 with the IGH gene on chromosome 14. 
This translocation is frequently found in PBL.   
 
Despite MYC gene aberrations being considered the primary driving force in PBL pathogenesis 
other genes such as BCL2, BCL6, MALT1, PAX5, CCND1 and PRDM1 (BLIMP1) have also been 
investigated. These studies yielded mix results, with rearrangements in these genes rarely 
being detected. However, gains of as much as 40%, were observed in some of these genes 
(Valera et al., 2010, Boy et al., 2011). CCND1 gene gains were identified for the first time in PBL 
and resulted in an increased expression of the protein cyclin D1. Cyclin D1 is a key cell cycle 
regulatory protein involved in uncontrolled cell proliferation and is observed as a possible 
determining factor in the aggressive nature of NHL such as PBL (Boy et al., 2011).  “Double-hit” 
(DH) phenomena, which may be found in DLBCL, are rarely found in PBL. Only one case has 
been reported thus far, showing  MYC and BCL2 translocations (Boy et al., 2011). PRDM1, 
encodes for BLIMP1, which regulates plasma cell differentiation and may be expressed in PBL. 
PRDM1 mutations are prevalent in PBL and may be associated with MYC translocation, gains 
and over expression. PRDM1 mutations may be considered by some as a second genetic 
aberration in many PBLs and could possibly lead to the over expression of BLIMP1 protein 





1.3.2 MYC aberrations in other lymphomas 
MYC dysregulation in B-cell lymphomas may occur as either a primary or secondary event.  In 
Burkitt lymphoma (BL) it presents as a primary event, while PBL, mantle cell lymphoma (MCL)  
and DLBCL it presents as a secondary event (Nguyen et al., 2017). Primary effusion lymphoma 
(PEL) with plasmablastic phenotype, which is a differential diagnosis for PBL,  does not exhibit 
either primary or secondary MYC aberrations (Campo et al., 2017).  BL  was the first lymphoma 
that described MYC rearrangement and are observed  in about 90% of  cases (Adams et al., 
1983, Alamri et al., 2017). In most  cases of BL, IGH is the translocation partner, with a small 
percentage being associated with immunoglobulin light chains (Dawson et al., 2007). In BL, 
MYC rearrangements are therefore a useful diagnostic aid, and is most often associated with a 
simple karyotype (Slack and Gascoyne, 2011). MYC translocations have been identified in about 
5-14% of DLBCL. As with many B-cell lymphomas, the IG breakpoints occur in the class 
switching regions which provides evidence that the IG/MYC translocations may occur in the 
germinal centre (Pedersen et al., 2019). In DLBCLs rearrangements in the MYC gene may be 
accompanied by re-arrangements in other genes such as BCL2 and BCL6. In cases where MYC 
rearrangements occur together with rearrangements in BCL2 or BCL6, they are referred to as 
double , and triple hit lymphomas if all three genes are re-arranged (Swerdlow, 2014, Rosenthal 
and Younes, 2017, Slack and Gascoyne, 2011). These phenomena are however uncommon in 
PBL. 
 
1.3.3 Detection of MYC gene aberrations 
There are two methods clinically available for MYC gene analysis,  conventional karyotyping 
and fluorescent in situ hybridisation (FISH), with FISH being the most commonly used 
methodology (Nguyen et al., 2017). For diagnostic FISH in Anatomical Pathology, formal fixed 
paraffin embedded (FFPE) tissue is the preferred method, as conventional karyotyping  
requires  fresh tissue (Nguyen et al., 2017) . There are two types of FISH probes used to detect 
MYC translocations. These are dual colour break apart rearrangement probes and dual colour 
dual fusion probes. The dual colour break apart rearrangement probe detects a MYC 
translocation without identifying the partner gene, while the dual colour dual fusion probe is 
15 
 
able to detect a MYC translocation and the partner gene involved (Dawson et al., 2007, Nguyen 
et al., 2017).   
 
1.4 Epstein-Barr virus (EBV) 
EBV or human herpesvirus - 4 (HHV-4) is a human gamma herpesvirus. EBV is a double stranded 
DNA virus and it is estimated that approximately 90% of the human population is infected by 
the age of 40 years (Rezk et al., 2018). EBV was first discovered more than 50 years ago by 
Anthony Epstein and Yvonne Barr in BL cell lines (Epstein et al., 1964, Young et al., 2016).  
 
1.4.1 Initial infection 
Infection with EBV in humans usually occurs via contact with infected saliva, but may also be 
transmitted through blood, semen and organ transplants.  EBV infects the epithelial cells and 
resting B -cells of the Waldeyer’s ring of the oropharynx and tonsillar crypts, where replication 
takes place (Longnecker et al., 2013) (Figure 1.5).  
 




Two different routes exist by which EBV glycoprotein binds to human epithelial cells and B-cell 
receptors. The infection of B-cells by EBV is well documented, however, EBV’s entry into 
mucosal epithelium was not fully understood. The first route of infection is of the epithelial 
cells, and involves the EBV membrane glycoprotein BMRF2, which binds to the beta1 family 
integrins on the cell surface (Xiao et al., 2008).  Ephrin receptor A2 (EphA2) on epithelial cells 
is responsible for EBV glycoprotein binding to these cells, and upregulation of EphA2 leads to 
an increase in epithelial cell infection by EBV (Chen et al., 2018, Zhang et al., 2018). However, 
it is also known that tonsillar epithelial cells may express CD21 on their surface, which would 
satisfy the more B-cell like route of infection, described below (Longnecker et al., 2013). 
 
The second route is of infecting the B-cells, which is the primary objective of EBV. This infection 
enables EBV of maintaining a lifelong persistent infection. The binding mechanism of EBV to 
resting B-cells is facilitated by CD21 and MHC class II molecules on the surface of these cells. 
CD21, also known as complement receptor 2 (CR2), binds to EBV membrane glycoprotein 
GP350/220 (Longnecker et al., 2013, Hutt-Fletcher, 2017, Hutt-Fletcher, 2014, Hutt-Fletcher, 
2007). After these initial fusions with the plasma membranes of epithelial cells or endocytic 
membranes of B-cells, the viral capsid is released into the cytoplasm and the linear viral 
genome is transported to and enters the nucleus via the nuclear pores.  The viral genome then 
circularises and assembles into chromatin, and is often referred to as a viral episome, 
resembling a small human chromosome (Longnecker et al., 2013, Lieberman, 2015), with host 
chromosomal integration very rarely occurring (Morissette and Flamand, 2010). In the human 
host, EBV may exist in certain cells in either the latent phase or the lytic phase. During the 
latent phase only, certain latent proteins are expressed, while during the lytic phase, viral 
replication occurs. During either of these phases, the viral genetic material is preserved in the 
form of circular extrachromosomal DNA. Circularisation occurs in many herpes viruses and is 
thought to protect the ends against the effect of cellular nucleases (Takayuki and Tatsuya, 
2014, Morissette and Flamand, 2010).  
  
Indicators of initial infection include episodes of typical cold like symptoms, characterised by 
fever, sore throat and headaches. In teenagers and/or adults, EBV can cause infectious 
mononucleosis (IM), also known as mono or kissing disease (Louten, 2016). EBV infection is 
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typically asymptomatic in healthy individuals and is controlled by the immune system, 
particularly the CD8+ cytotoxic T-cells. EBV is however also associated with  malignancies such 
as PBL, BL and nasopharyngeal carcinoma (NPC) (Hatton et al., 2014). 
 
1.4.2 Latent Infection 
During the EBV latency program up to 8 different EBV encoded proteins and non-coding RNAs 
are expressed. A pre-latent phase begins soon after initial infection, and thereafter four 
traditional latent phases occur. These are latency 0, 1, 2 and 3, and each of these latent phases 
results in the expression of various latent proteins and the repression of lytic genes. During the 
pre-latent phase, certain lytic and latent genes are expressed and EBV infects both epithelial 
and resting B-cells. Replication does not occur in the epithelial cells but takes place in the 
resting B-cells. These infected B-cells start to enlarge into blast cells and begin proliferation, 
with viral DNA becoming detectable. It is also during this phase that cellular chromatin is 
acquired, and eventually lytic genes are silenced. The pre-latent phase is complete about 14 
days post infection (Hammerschmidt, 2015, Kempkes and Robertson, 2015, Price and Luftig, 
2015).  
 
EBV then enters a latency 3 phase (also referred to as the growth program) during which time 
all the protein encoding genes are expressed. These include the Epstein-Barr virus nuclear 
antigens (EBNA1, 2, 3A, 3B, 3C), latent membrane proteins (LMP1, LMP2a and LMP2b), the 
Epstein-Barr virus encoded RNAs (EBERs) and miRNAs. During latency 3, EBV drives the 
proliferation and differentiation of the B-cells into memory B-cells and expresses proteins that 
allow for bypassing of the normal host B-cell differentiation (Table 1.1). This proliferation of B-
cells is curtailed to a certain degree by CD4+ helper and CD8+ cytotoxic T-cells (Heuts et al., 
2014). The expression of all the EBV gene products during latency 3 allows for escape of normal 
immune surveillance in post-transplant and HIV associated immune suppressed patients 





Table 1.1: The proteins expressed during the EBV latency types. 
Latency 0 Latency 1 Latency 2 Latency 3 
   EBNA-LP 
 EBNA1 EBNA1 EBNA1 
   EBNA2 
   EBNA3 
  LMP1 LMP1 
  LMP2 LMP2 
EBER EBER EBER EBER 
BART miRNA  BART miRNA BART miRNA BART miRNA 
 
It is believed that all the other latency programs are generated from type 3 latency infected B- 
cells that pass through into the germinal centres of lymph nodes. This leads to the expression 
of latent proteins EBNA1, LMP1, LMP2 and EBER, which is in keeping with a type 2a latency 
pattern (Heuts et al., 2014). Even though latency type 2 is categorised as type 2a and 2b, they 
do not necessarily occur concurrently. Latency 2b was first observed in the primary infection 
of B-cells in patients with chronic lymphocytic leukaemia and was named latency 2b because 
the protein expression was directly opposite to that of latency type 2a. Further research 
showed that type 2b latency actually occurred just before latency 3 (Price and Luftig, 2015). 
After exiting the germinal centres of the lymph nodes and entering circulation, the latently 
infected B-cells express only EBER’s and miRNAs. No other EBV proteins are expressed and this 
is referred to as latency 0.  Latency 1 occurs when only EBNA1 is expressed briefly during the 
cell cycle. Latency 0/1 is sometimes also referred to as restricted or true latency, and results in 
complete immune surveillance evasion (Kliszczewska et al., 2017). 
 
1.4.3 EBV Latent protein location and function 
1.4.3.1 EBNA1  
Epstein-Barr nuclear antigen 1 (EBNA1) is expressed during latency 1, 2 and 3. EBNA1 is 
however not expressed in latency 0 which occurs in resting memory B-cells. It is thought to be 
expressed briefly during the cell cycle, resulting in EBV latency 1 for a brief period (Rezk et al., 
2018).  It is expressed in the nucleus and is considered the viral genome maintenance protein 
and may be expressed in both lytic and latent EBV infection. EBNA1 depletion in latently 
infected cells may lead to EBV reactivation and is credited as the driving force in EBV moving 
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from a latency cycle to a lytic one (Frappier, 2012, Sivachandran et al., 2012). EBNA1 also plays 
a role in the transcriptional regulation of other latent nuclear and membranous proteins and 
is not recognised by the cytotoxic T-cells (Rezk et al., 2018, Sivachandran et al., 2012).  
 
1.4.3.2 EBNA2 
Epstein-Barr nuclear antigen 2 (EBNA2) and Epstein-Barr nuclear antigen leader protein (EBNA-
LP) are co-expressed soon after EBV infection of B-cells. EBNA2 is expressed during latency 3 
only in the nucleus of infected cells and is essential for B-cell transformation. Both EBNA2 and 
EBNA-LP are associated with binding to upstream elements of MYC and MYC regulated genes. 
This may result in an increased MYC driven cellular proliferation (Rezk et al., 2018, Kang and 
Kieff, 2015).  
 
1.4.3.3 EBNA3 Family 
Epstein-Barr nuclear antigens 3A/3B/3C (EBNA3A/3B/3C) belong to a family of genes that have 
the same promoter, have similar gene structures and are similarly regulated. The EBNA3 family 
is expressed during latency 3 only and is expressed in the nucleus of infected B-cells. The entire 
EBNA3 family functions as coactivators of EBNA2. EBNA3A functions as a transcriptional 
regulator that influences viral and cellular gene expression. EBNA3A may also play a role in B- 
cell transformation. The inactivation of EBNA3B, which is the EBV-encoded tumour suppressor 
drives lymphomagenesis and immune evasion. EBNA3B also upregulates CXCL10 and has a 
growth inhibitory role. Among the 6 latent nuclear proteins, EBNA3B is the only dispensable 
protein for B-cell transformation. EBNA3C coactivates the LMP1 promoter with EBNA2, and 
induces disturbances of various cell-cycle checkpoints, which promotes cell proliferation and 
induces G1 arrests. These are essential for EBV mediated B-cell transformation (Rezk et al., 
2018, Kang and Kieff, 2015). 
 
1.4.3.4 EBNA-LP 
Epstein-Barr nuclear antigen leader protein (EBNA-LP), is also sometimes referred to as EBNA5, 
and is expressed during latency 3 only. EBNA-LP is expressed in the nucleus of infected cells. 
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EBNA-LP is one of the first viral proteins produced by EBV. The main function of EBNA-LP is 
coactivator of EBNA2 and is also responsible for driving resting B-cells into the G1 or growth 
phase of the cell cycle by binding and inactivating cellular P53 (Kang and Kieff, 2015, Rezk et 
al., 2018, Thompson and Kurzrock, 2004).  
 
1.4.3.5 LMP1 
Latent membrane protein 1 (LMP1) is expressed during latency 2 and 3. LMP1 is expressed in 
the cytoplasmic membrane of infected B-cells. LMP1 is involved in B-cell transformation and 
can mimic the active receptor CD40 by associating with the same tumour necrosis factors. 
LMP1 has also been recognised as the primary transforming gene product of EBV. LMP1 is 
expressed in many EBV associated lymphoproliferative diseases and is directly linked to 
oncogenesis. LMP1 is also linked to enhanced expression of B-cell adhesion molecules, 
enhanced expression of B-cell activation molecules and cellular clumping. By causing the 
overexpression of BCL2, it protects infected B-cells from P53 induced apoptosis (Thompson 
and Kurzrock, 2004, Kieser and Sterz, 2015, Rezk et al., 2018).  
 
1.4.3.6 LMP-2A and LMP-2B 
Latent membrane protein 2A/2B (LMP-2A/2B) is expressed during latency 2 and 3. Both LMP-
2A and 2B are coded by the same LMP-2 gene. LMP-2A and 2B are expressed in the cytoplasmic 
membrane of infected B-cells. EBV infected cells are prevented from entering the lytic cycle by 
LMP2A, which can sequester tyrosine kinase from BCR and thereby result in the inhibition of 
BCR signalling. LMP2A is therefore able to mimic BCR and replace survival signals for B-cells. 
LMP-2B negatively regulates LMP-2A functions in preventing the switch from latent to lytic 
replication. LMP-2A and 2B modifies normal B-cell development in favour of an EBV latency 
program (Rezk et al., 2018, Thompson and Kurzrock, 2004). 
 
1.4.3.7 EBER-1 and EBER-2 
EBER 1 and 2 are expressed abundantly in the nuclei of almost all EBV infected B-cells, during 
all latency programs. The EBER’s are non-polyadenylated RNAs that are not essential for the 
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EBV-induced transformation of B-cells. They also play a role in inducing the production of IL-
10, which might suppress cytotoxic T cells and stimulate growth of infected B-cells. EBERs have 
also been thought to play a modulatory role of the pathways important in interferon response 
(Thompson and Kurzrock, 2004, Rezk et al., 2018). 
 
1.4.3.8 BARTs 
BamHI fragment A rightward transcripts (BARTs) are EBV miRNAs that are expressed in the 
nucleus of EBV infected cells during all forms of latency. The main function of BARTs are to act 
as epigenetic regulators of the microenvironment which is conducive for EBV latency. BARTs 
also enable EBV to evade the host immune response. The exact role of BART in tumourigenesis  
and possible treatment target is subject of much research (Verhoeven et al., 2019).  
 
1.4.4 Lytic infection and reactivation 
After initial infection the virus embarks on a short lytic program before adopting a lasting or 
persistent latent infection. Only a small percentage of infected cells switch from the latent to 
the lytic phase (Takayuki and Tatsuya, 2014). During the latent phase in infected B-cells, EBV 
exists as a nuclear episome, which is replicated once per cell cycle with the aid of the hosts 
DNA polymerase (Kenney and Mertz, 2014). During the lytic cycle, all the viral lytic genes are 
expressed, including the virus’s transcription factors BZLF1 and BRLF1 as well as a viral DNA 
polymerase catalytic subunit (Takayuki and Tatsuya, 2014, Kenney and Mertz, 2014).  
 
The life cycle of EBV may be referred to as biphasic since the virus may alternate between a 
latent or lytic phase (Hammerschmidt, 2015, Takayuki and Tatsuya, 2014). Reactivation may 
be divided into three phases viz intermediate early (IE), early (E) and late (L).  During IE, two 
transcription factors are expressed. Two viral genes BZLF1 and BRLF are transcribed to encode 
the transactivator proteins BZLF1 also known Zta and BRLF1, also known as Rta (Li et al., 2016). 
The entire EBV reactivation and drive to the lytic phase may be triggered by BZLF/Zta and 
BRLF/Rta, which belong to the same transcription factor family.  These transcription factors are 
never expressed during the latent phase, due to silencing by transcriptional repressors (Kenney 
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and Mertz, 2014). This is followed by an early phase (E) during which time the proteins involved 
in DNA replication are produced. The last phase is the late phase (L), during which time the 
virions are formed (Thorley-Lawson et al., 2013). Activation of the lytic program and replication 
of EBV appears to take place in the circulating B-cells that move through the lymphoid tissue 
in the oropharyngeal epithelial cell mucosa. The virus then passes into the epithelial cells, 
where it is amplified and shed in the saliva for possible infection (new host or present host B-
cells) to establish a lifelong persistence (Hutt-Fletcher, 2014, Hutt-Fletcher, 2017).  
 
1.4.4.1 Mechanism of reactivation 
BZLF1/Zta, also sometimes referred to as ZEB1, is the major trigger of the EBV lytic cycle of 
events and may be activated in B-cells by a variety of physiological stimuli as well as chemical 
agents (Kenney and Mertz, 2014). The amount of BZLF1 expression determines whether EBV 
is in a latent form or in a reactivated form (Murata, 2014, Takayuki and Tatsuya, 2014). Surface 
B-cell receptor (BCR) is stimulated, which results in signal transmission to the latent virus in the 
nucleus. This BCR signal activation causes the expression of BZLF1. When there is sufficient 
circulating antibodies, BCR is not stimulated and EBV remains in latency (Takayuki and Tatsuya, 
2014). When there is a decrease in serum antibodies or increase in antigens, this is thought to 
simulate EBV lytic reactivation (Takayuki and Tatsuya, 2014). However, the precise method of 
reactivation is the topic of much research, and another widely accepted theory is that lytic 
replication may be linked to differentiation of cells that are latently infected by EBV. It is further 
purported that when B-cells differentiate into plasma cells, the lytic phase is induced by the 
plasma cell differentiation factor XBP-1. However, it has also been suggested that when LMP1 
down-regulates the B-lymphocyte - induced maturation protein 1, (BLIMP1), plasma cell 
differentiation is disrupted which leads to EBV lytic replication regulation (Longnecker et al., 
2013). It should also be considered though, that LMP1 which may be detected in EBV positive 
PBL, is only expressed during latency 2 and 3.  
 
1.4.5 Oncogenesis  
EBV needs to maintain its viral genome in the infected B-cell but must avoid killing the cell, in 
order to remain oncogenic. Furthermore, EBV must prevent the infected cell from being 
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targeted by the human immune response, by means of cellular growth control pathway 
intervention (Thompson and Kurzrock, 2004, Price and Luftig, 2015). When EBV establishes 
true latency and the only EBV proteins expressed are EBERs and or EBNA1, the host immune 
surveillance is evaded, and the cells are not pathogenic (Price and Luftig, 2015). Viral DNA, 
which exists as an extra chromosomal episome in the nucleus, still needs to be maintained, 
and is transmitted via cell progeny when B-cells replicate. Although these cells are not 
transformed or acquire oncogenic mutations, they may become neoplastic (Thompson and 
Kurzrock, 2004). Potential oncogenesis by EBV occurs in a multistep approach. It is thought to 
occur  during latency 3, when the full repertoire of EBV proteins are expressed (Murata et al., 
2014). LMP1 and LMP2A, which are two known and frequently identifiable and studied EBV 
oncogenes, are encoded and act in concert. The function of LMP1 is to elicit growth promoting 
signals by mimicking the CD40 signalling pathway. LMP2A is structurally like and functions 
identically to the BCR. It is likely that due to LMP1’s ability to mimic CD40 and LMP2A’s ability 
to mimic BCR in the germinal centre, also allows for the deregulation of the host immune 
system (Murata et al., 2014). EBNA 3A and 3C play a critical role in the maintenance and 
formation of neoplastic cells by silencing tumour suppressor genes (Vega et al., 2004, Murata 
et al., 2014).  
 
EBER, which is present during all latencies is constantly under investigation and has also been 
implicated in oncogenesis, but its precise role needs further research.  
The escape from the host immunity, by virtue of a systematic suppression of the immune 
system by HIV, may result in the emergence of certain EBV positive B-cell lymphomas such as 
PBL (Murata et al., 2014). The role of immune suppression contributes to latently infected cells 
in the peripheral blood to increase in number. EBV is also able to activate intracellular signalling 
involved in the control of cell proliferation (Thompson and Kurzrock, 2004). A further method 
of immune evasion by EBV, involves the expression of EBNA1 Gly/Ala repeat sequence, which 






1.4.6 Latency in PBL 
The EBV latency pattern most commonly reported in PBL is latency type 1, but latency 2 and 
latency 3 have also been reported.  In latency 1, EBER, EBNA1 and miRNAs (BARTs) are the only 
EBV proteins expressed and complete host immune evasion is maintained (Rezk et al., 2018, 
Rezk and Weiss, 2007).  EBV Latency type 2 was reported in a study by Ambrosio et al., 2017, 
when EBER, EBNA1 and LMP2 proteins were expressed (Ambrosio et al., 2017). However, 
latency 3, where all EBV latent proteins are expressed, has been reported in cases of HIV 
positive oral cavity PBL and post-transplant immunosuppression (Bibas and Castillo, 2014, 
Castillo et al., 2015).  
 
1.4.7 EBV Latency in other lymphomas and malignancies 
The table below (Table 1.2), provides a summary of the various EBV associated disorders and 
the EBV latent protein expression. Many of these EBV related disorders are often associated 
with a coinfection with HIV as in the case of DLBCL, immunodeficiency associated BL and EBV 
associated smooth muscle tumour (EBV-SMT). EBV related disorders may also be associated 
with other pathogens such as the malaria parasite plasmodium falciparum in the case of 
endemic BL. 
 
Table 1.2: EBV Latency in other lymphomas and malignancies (Rezk, 2018) 
Disease EBV 
Frequency 
EBV Latency Latent protein expression 
pattern 
Hodgkin lymphoma 40% Latency 2 EBNA1, LMP1, LMP2 
Burkitt lymphoma 20-95% Latency 1 EBNA1 
Primary effusion lymphoma >90% Latency 1/2 EBNA1 and or LMP1, LMP2 
Diffuse large B-cell lymphoma 30-60% Latency 3 EBNA1, 2, 3, LP, LMP1, LMP2 
Primary CNS lymphoma >95% Latency 3 EBNA1, 2, 3, LP, LMP1, LMP2 
Nasopharyngeal carcinoma >80% Latency 3 EBNA1, 2, 3, LP, LMP1, LMP2 
EBV associated smooth 
muscle tumour 






1.5 Rationale for doing this research 
The rationale for doing this research is to gain a better understanding of the pathogenesis of 
PBL in the context of EBV infection. To understand how each EBV gene product during the 
latent phase contributes (if at all) to the pathogenesis of PBL and to determine if these 
correlate with any clinical or histopathological parameters. The goal is to understand EBV-
related diseases with a view to effective prevention and treatment strategies. In the SA 
context, EBV latency in PBL has not been previously investigated. Determining the MYC gene 
status will provide some insight with regards to the prognostic value of this marker in our 
setting. Patients may be stratified according to their MYC gene status to receive targeted 
treatment or closer follow-up. It is also observed that the median survival of patients is greatly 
reduced when MYC rearrangements were present. 
 
 
1.6 Aims and objectives   
1. To characterise the EBV latency in a cohort of patients diagnosed with PBL at GSH, by 
means of immunohistochemistry. 














MATERIALS AND METHODS 
 
2.1 Ethics approval 
Scientific approval for the study was obtained from the Department of Pathology Research 
Committee, Faculty of Health Sciences, University of Cape Town.  Thereafter, the protocol was 
approved by the Human Research Ethics Committee (HREC) of the Faculty of Health Sciences, 
University of Cape Town (HREC Ref Number: 533/2017). 
 
2.2 Study design 
A search of the National Health Laboratory Service (NHLS) laboratory information systems 
(DISA and Trak) in the Division of Anatomical Pathology, Groote Schuur Hospital (GSH) was 
performed for all cases diagnosed as PBL from 2005 to 2017. Patient information such as age, 
gender and HIV status were recorded, in addition to all diagnostic immunohistochemistry (IHC) 
results. This information was collated into a Microsoft Excel (Microsoft, Redmond, Washington, 
USA) spreadsheet and patient identifiers were removed to ensure patient confidentiality. The 
cases were then assigned a randomised study number. All study information and material were 
securely stored for the duration of the study. SPSS (IBM, New York, USA) statistical software 
was used to analyse all patient demographic information as well as EBV and MYC test results. 
 
2.3 Sample selection 
The slides for the selected cases were retrieved from the archives of the Division of Anatomical 
Pathology, NHLS, Groote Schuur Hospital. The PBL diagnosis was reviewed, confirmed and 
thereafter the wax blocks were retrieved.  The inclusion criteria included a confirmed diagnosis 
of PBL and adequate, well preserved tissue. Cases with insufficient or poorly preserved tissue, 
ALK+ immunohistochemistry as well as duplicate cases were excluded.   
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2.4 Immunohistochemical staining 
To determine the EBV latency status, 3 immunohistochemical stains were performed on each 
EBV positive case, using three primary antibodies viz., EBNA1, EBNA2 and LMP1. In order to 
rule out ALK-positive LBCL, which exhibits a similar immunophenotype as PBL, ALK IHC was 
performed on selected cases (all EBV negative cases and a random selection of EBV positive 
cases)  
 
2.5 Immunohistochemical staining protocol 
Immunohistochemistry was performed using the commercially available Envision+ HRP System 
Labelled Polymer Anti-Mouse kit (DAKO/Agilent, Santa Clara, CA, USA). The preparation of all 
buffers and reagents used in the staining protocol are listed in Appendix 1. Three-micron tissue 
sections were cut on a Leica Rotary Microtome RM2125 RTS (Leica Biosystems Inc GmbH, 
Wetzlar, Germany), floated on a water bath (Sakura Finetek, Nihonbashi-Hamacho, Chuo-ku, 
Tokyo, Japan) and picked up on coated HISTOBOND® slides (Paul Marienfeld GmbH & Co, 
Lauda-Königshofen, Germany). The sections were then heat fixed on a hotplate (Hospital and 
Laboratory Supplies Ltd, London, England) at 60oC for 10-15 minutes. Thereafter, the sections 
were dewaxed through a series of xylene baths, cleared in ethanol and hydrated in running tap 
water for 5 minutes. Antigen retrieval was performed using the conventional pressure cooker 
method. Each antibody required a specific buffer solution for antigen retrieval (Appendix 1, 
Table 2.1), but the process of antigen retrieval remained the same. Either a citric acid buffer 
(pH6) or Tris/EDTA buffer (pH9) was used. The antigen retrieval buffer was poured into the pot 
of the pressure cooker and was placed on a heating plate (J.P. Selecta S.A, Autovia, Barcelona, 
Spain), to get to a rolling boil. The slides were placed into a stainless-steel slide rack and 
submerged in the boiling solution. The pressure cooker lid was placed on the cooker and the 
timer was set.  After 1 minute and 30 seconds, the pressure cooker was removed from the 
heating plate and placed under a stream of running tap water to allow the pressure to drop for 
the lid to be removed safely. The slides were then allowed to cool down in the buffer solution 
for a further 30 minutes and then washed in running tap water for 2-3 minutes. 
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Key:  ALK=Anaplastic lymphoma kinase, EBV=Epstein-Barr virus, EBNA1=Epstein-Barr nuclear 
antigen 1, EBNA2=Epstein-Barr nuclear antigen 2, LMP1=Latent membrane protein 1, T/EDTA 
- Tris EDTA, PBS=Phosphate buffered saline 
 
The sections were then flooded with a 3% solution of H2O2 (Appendix 1) and incubated for 10 
minutes at room temperature (RT) to block endogenous peroxidase activity. The sections were 
then washed in running water for 2-5 minutes and then with PBS/Tween (Appendix 1) for 5 
minutes. A 5% solution of normal goat serum (Appendix 1) was applied to the sections and 
allowed to incubate for 15 minutes at RT to block nonspecific antibody binding. The goat serum 
was wiped from around the sections and edges of the and marker pen (DAKO/Agilent, Santa 
Clara, CA, USA) was used to circle around the sections to prevent antibody run off. One 
hundred microliters of diluted primary antibody was applied to each section (Table 2.1), and 
allowed to incubate for 1 hour at RT. After 1 hour, each slide was rinsed off with PBS (Appendix 
1) and then washed for a further 5 minutes in PBS/Tween. Two drops of Envision+ HRP System 
Labelled Polymer Anti-Mouse (DAKO/Agilent, Santa Clara, CA, USA) was applied to each section 
and incubated for 30 minutes at RT. Each slide was then rinsed with PBS and washed for a 
further 5 minutes in PBS/Tween. The working DAB solution (Appendix 1) was then prepared. 




After staining with DAB, the sections were washed in running tap water for 5 minutes and then 
counterstained with Mayer’s haematoxylin (Appendix 1) for 3 minutes. Thereafter, the sections 
were rinsed in running tap water and the nuclei were blued in bluing solution (Appendix 1) for 
30 seconds. The slides were dehydrated in alcohol and cleared in xylene (Merck KGaA, 
Darmstadt, Germany). The slides were then cover slipped using glass coverslips (Paul 
Marienfeld GmbH & Co, Lauda-Königshofen, Germany) and Entellan (Merck KGaA, Darmstadt, 
Germany). A positive and negative control was included in each batch of immunohistochemical 
stains. The positive control was either NPC tissue or EBV-SMT, while the negative control 
excluded the application of the primary antibody with PBS used as a substitute (Appendix 3). 
 
2.5.1 Interpretation of EBV immunohistochemical stains 
The immunohistochemical stains were evaluated using an Olympus BX43F (Olympus, Shinjuku, 
Tokyo, Japan) microscope. Staining was scored as either positive, showing a brown DAB 
staining reaction, or negative, when showing the lack thereof.  EBNA1 and EBNA2 have a 
nuclear localisation while LMP1 has cytoplasmic or membranous localisation in the tumour 
cells.   
 
2.5.2 Immunohistochemistry optimisation 
The optimisation strategy for each antibody included determining the optimal dilution, and 
antigen retrieval solution (Table 2.1).   
 
2.6 CD246, ALK Protein (Anaplastic Lymphoma Kinase) ALK1 clone   
The selected FFPE wax blocks were sectioned at 3µm, using a Leica Rotary Microtome RM2125 
RTS (Leica Biosystems Inc GmbH, Wetzlar, Germany). The sections were heat fixed on a 
hotplate (Hospital and Laboratory Supplies Ltd, London, England) at 60oC for 10-15 minutes. 
The slides were then placed on the Ventana XT auto-stainer (Roche Diagnostics, Basel, 
Switzerland). The protocol included dewaxing using EZ Prep (Roche Diagnostics, Basel, 
Switzerland), antigen retrieval for 64 minutes in CC1 (Roche Diagnostics, Basel, Switzerland), 
primary antibody incubation for 36 minutes and detection using Optiview DAB.   On completion 
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of the protocol, the slides were removed from the auto-stainer, washed briefly in diluted 
detergent and water, and then stained in haematoxylin for 3 minutes. The slides were washed 
in water, placed in bluing solution (Appendix 1) for 30 seconds and rinsed in running tap water 
for another minute. The slides were dehydrated in alcohol and cleared in xylene (Merck KGaA, 
Darmstadt, Germany). The slides were then cover slipped using glass coverslips (Paul 
Marienfeld GmbH & Co, Lauda-Königshofen, Germany) and mounted in Entellan (Merck KGaA, 
Darmstadt, Germany). A positive and negative control was included in each batch of 
immunohistochemical stains. The positive control was ALK-positive ALCL tissue while the 
negative control excluded the application of the primary antibody with PBS used as a substitute 
(Appendix 3). 
 
2.6.1 Interpretation of ALK staining 
The processed slides were evaluated using an Olympus BX43F (Olympus, Shinjuku, Tokyo, 
Japan) microscope.  Staining was interpreted as positive when brown DAB staining was 
observed in the nuclei and/or cytoplasm of the tumour tissue.  
 
2.7 EBER In Situ Hybridisation 
EBER ISH was performed on earlier cases when EBER ISH was not available on the diagnostic 
platform.  This test was performed on the Roche Ventana XT auto-stainer (Roche Diagnostics, 
Basel, Switzerland). The FFPE wax blocks were sectioned at 3µm, using a Leica Rotary 
Microtome RM2125 RTS (Leica Biosystems Inc GmbH, Wetzlar, Germany) and mounted on 
coated HISTOBOND® slides (Paul Marienfeld GmbH & Co, Lauda-Königshofen, Germany).  The 
slides were then heat fixed on the hotplate (Hospital and Laboratory Supplies Ltd, London, 
England) at 60oC for 10-15 minutes. Thereafter slides were placed on the Roche Ventana XT 
auto-stainer (Roche Diagnostics, Basel, Switzerland). The protocol included dewaxing with EZ 
Prep (Roche Diagnostics, Basel, Switzerland), antigen retrieval using CC2 (Roche Diagnostics, 
Basel, Switzerland), probe denaturation and hybridisation and detection. The indirect 
detection method involved the use of an antibody and substrate-chromogen linked enzyme 
system. After completion of the protocol, the slides were removed and placed in a stainless-
steel rack for the post staining dehydration procedure. The liquid coverslip (LCS) was removed 
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from the slide by washing in a mild detergent and the slides were then washed in running tap 
water for about a minute. After washing in water, the slides were then washed in grade 
alcohols (80-100%) for about 2 minutes each and then dipped into acetone briefly for 10 times. 
The slides were cleared in three baths of xylene (Merck KGaA, Darmstadt, Germany) for 30 
seconds each. After clearing in xylene, the slides were cover-slipped using Entellan mounting 
media (Merck KGaA, Darmstadt, Germany). A positive control was included with each batch of 
EBER ISH. The positive control was either EBV-SMT or NPC tissue. 
 
2.7.1 Analysis of EBER ISH  
The processed slides were analysed using an Olympus BX43F (Olympus, Shinjuku, Tokyo, Japan) 
light microscope. A dark blue stain present in nuclei of the tumour cells indicated a positive 
EBER result. 
 
2.8 Fluorescence in situ hybridisation (FISH) 
FISH was performed on all cases in the cohort. The H&E and/or most recent 
immunohistochemical stained slide were used to identify the most suitable area to perform 
FISH, as the whole section was not used. Areas of necrosis, traction distortion and 
haemorrhage were avoided and an area 5mm x 5mm was identified and circled with a fine 
liner.  Using a Leica Rotary Microtome RM2125 RTS (Leica Biosystems Inc GmbH, Wetzlar, 
Germany), 4µm sections were cut and mounted on HISTOBOND® slides (Paul Marienfeld GmbH 
& Co, Lauda-Königshofen, Germany).  The slides were then dried in an incubator (Memmert 
GmbH, Schwabach, Germany) at 37o C overnight. The next day, the slides were dewaxed in 
three changes of xylene for 5 minutes each and then three changes of graded alcohol of 70%, 
85%, 100% concentrations (Appendix 1) for 2 minutes each. The slides were air dried and then 
treated in 0.2N HCl at 37oC in a water bath for 20 minutes. Thereafter, the slides were washed 
in deionised water for 5 minutes followed by a wash in 2xSSC (Appendix 1) for 5 minutes at RT. 
Antigen retrieval was performed using 1M sodium thiocyanate (NaSCN) at 80oC in a water-bath 
for 30 minutes. (Appendix 1) After antigen retrieval, the slides were washed in 2xSSC for 10 
minutes at RT and then for 5 minutes in deionised water. The tissue sections were then 
digested in 0.05% pepsin/0.01N HCl at 37oC in a water bath for between 16-30 minutes.  At 
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the end of the digestion, the slides were washed in deionised water for 2 minutes, dehydrated 
in graded alcohols for 2 minutes and allowed to air dry in a darkened cupboard. Thereafter, 
the probe, Vysis LSI MYC Dual Colour Break Apart Rearrangement Probe (Abbott Laboratories, 
Illinois, USA) (Table 2.1), was prepared according to manufacturer instructions (Appendix 1, 
Table 5.1). Five microliters of the probe mix was applied to each section and coverslipped. The 
edges of the coverslip were sealed using Fixogum rubber cement (Marabu GmbH & Co. KG, 
Bietigheim-Bissingen, Germany). The slides were then placed on a slide hybridiser 
(DAKO/Agilent, Santa Clara, CA, USA). The denaturation and hydridisation conditions for the 
MYC probe were as follows: Denaturation at 73oC for 5 minutes and then hybridisation at 37oC 
for 24hrs. After hybridisation, the coverslip of the section was gently removed, and the slides 
were washed in 2X SSC/0.3% IGEPAL CA-630 post hybridization buffer at RT for 2 minutes. 
Thereafter, slides were washed in 2X SSC/0.3% IGEPAL CA-630 post hybridisation buffer at 72oC 
in a water bath for 2 minutes and 10 seconds. The slides were then removed, the edges and 
around the sections were dried and the slides were placed in a darkened cupboard to dry 
completely. Thereafter, the sections were mounted in 5 µl of DAPI II counterstain (Abbott 
Laboratories, Illinois, USA) and coverslipped.  The edges of the coverslip were sealed using clear 
nail polish and allowed to dry in a dark cupboard. A DLBCL with a MYC translocation served as 
the positive control while a reactive lymph node served as the negative control. 
 
Figure 2.1: Diagrammatic representation of the MYC FISH probe map. The 277kb 
SpectrumOrange probe is designed to anneal centromerically to the 5’ end, while the 407kb 
SpectrumGreen probe is designed to anneal telomerically to the 3’ end of the MYC gene.   
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2.8.1 Analysis of MYC FISH  
The processed slides were viewed, analysed and photographed on a Zeiss Axioskop 40FL 
fluorescent microscope (HBO 100) fitted with the appropriate excitation and emission filters 
(Carl Zeiss AG, Oberkochen, Germany). At least 100-200 non-overlapping, intact nuclei in an 
area of tumour tissue were assessed.  Nuclei containing two orange/green (yellow) fusion 
signals indicated an intact MYC gene while nuclei showing one orange, one green and one 
orange/green (yellow) signal indicated MYC translocation. MYC gain was observed as 3-4 
orange/green (yellow) signals while MYC amplification was observed as >4 orange/green 
(yellow) signals. When scoring, a cut-off for structural and numerical aberrations of ≥5% was 
applied.  The expected FISH signal patterns are found in Figure  2.2 (Ventura et al., 2006). 
 
 
Figure 2.2: Anticipated FISH hybridisation pattern. Normal intact signal (top) and abnormal 
broken apart signal (bottom) (Ventura et al., 2006). 
 
2.8.2 Troubleshooting and optimisation 
Several parameters such as the appropriate pre-treatment procedure, digestion time and 




2.9 Statistical analysis 
Descriptive statistics were reported as frequencies or medians. Distributions of 
immunohistochemical scoring or FISH data with clinicopathological data was compared using 
the Chi-squared test or Fisher’s exact test. Differences were considered significant when the P 
value was less than 0.05 (two-side). The Statistical Package for Social Sciences (SPSS) v 26.0.0.0 



























3.1 Case selection 
A search of the TRAK and DISA laboratory information system databases, over a period of 13 
years, yielded 182 patients who were diagnosed with PBL at Groote Schuur Hospital. First, the 
reports were retrieved and information such as clinical history, macroscopy, microscopy, 
immunohistochemistry and pathological diagnosis were examined and confirmed. At this 
stage, 12 duplicate cases and 57 referrals were excluded. One additional case was excluded as 
it was positive for HHV8, which was in keeping with a diagnosis of PBL variant of MCD.  
Thereafter, the slides of 112 cases were requested from the archives of the Division of 
Anatomical Pathology; NHLS/UCT.  The slides were examined by a histopathologist to confirm 
the diagnosis and assess tissue fixation.  Core biopsies and poorly fixed tissue were excluded 
which resulted in 64 FFPE tissue blocks being requested from archives. Sixty blocks were 
received and re-examined during which time, another 11 blocks were excluded, leaving a 
cohort size of 49 cases.  
 
3.2 Patient clinical characteristics 
The PBL cohort comprised 49 cases of which 30/49 (61.2%) were male and 19/49 (38.8%) were 
female (Table 3.1).  The median age of the patients was 39 years while the ages ranged from 







Figure 3.1: Age distribution of PBL cases  
 
Of the 49 patients, the HIV status of 47 patients were known.  Of these 44/49 (89.8%) were 
HIV positive and 3/49 (6.1%) were HIV negative. Two cases were unknown. The site of tumour 
biopsy in 12/49 (24.5%) cases was nodal and 37/49 (75.5%) were extranodal. The most 
common extra nodal site was the upper aerodigestive tract (54.1%) followed by pelvis (18.9%) 












Table 3.1: Summary of PBL case information  
Patient demographics Total 
Gender Male 30 
Female 19 
Age Median 39 
Range 24-64 
HIV Status Positive 44 
Negative 3 
Unknown 2 
Site of biopsy Nodal 12 
Extranodal  37 
Upper aerodigestive tract 11 




Lower limb 2 
Neck 2 
Upper limb 1 
 
3.3 Pathological features 
3.3.1 Immunophenotype 
The diagnosis of PBL was in keeping with the WHO criteria i.e. the neoplastic cells expressed at 
least one plasma cell marker (CD38, CD138 or VS38C) and was negative for B-cell markers 
(CD20 and PAX5). Further, MUM1/IRF4 was positive in 22/49 (44.9%) of the cases.  HHV8 was 
negative for the 12 cases that were tested thereby excluding the diagnosis of HHV-8 positive 
plasmablastic variant of MCD. 
 
3.4 Immunohistochemical analysis  
 
3.4.1 CD246, ALK Protein expression 
An ALK-positive ALCL served as the positive control for the ALK immunohistochemistry. 
Assessment of the processed slides showed a DAB staining reaction in the nuclei and cytoplasm 
of the tumour cells (Figure 3.2A). In addition, there was no non-specific background staining. 
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This staining pattern was consistent with manufacturer specification. Of the 4 EBV positive and 
6 EBV negative PBL cases, none were positive for ALK (Figure 3.2B). In total, 18 cases were ALK 
negative including cases that were processed during the routine diagnostic workup. 
 
 
Figure 3.2: Anaplastic lymphoma kinase (ALK) staining in control and PBL cases. A. ALK-positive 
ALCL positive control (20x mag). B. ALK negative staining PBL case 12 (20x mag). 
 
3.4.2 EBER ISH 
An EBV positive NPC served as the positive control.  Assessment of the processed slides showed 
a dark blue, circumscribed homogenous nuclear staining pattern in all EBV infected cells (Figure 
3.3A). The background showed only the red/pink counterstain. A negative EBER ISH was 
confirmed by the absence of the dark blue nuclear staining. EBER ISH was performed on 27 
cases. Twenty-two cases were EBER positive, showing positivity in more than 5% of the tumour 
cells (Figure 3.3B) while 5 cases were considered negative (Figure 3.3C). In total, including cases 
that were processed during the diagnostic work up, 41/49 (83.7%) cases were EBV positive and 




Figure 3.3: EBER ISH staining in control and PBL cases. A. EBV positive NPC positive control (20x 
mag). B. Positive PBL case 12 (20x mag). C. Negative PBL case 16 (20x mag). 
 
3.4.3 EBNA1 
EBV positive NPC tissue served as the positive control and showed a DAB staining reaction in 
the nuclei of the tumour cells (Figure 3.4A). There was no non-specific background staining in 
any of the slides processed including the negative control (Figure 3.4B). This staining pattern 
was consistent with the manufacturer specification.   EBNA1 was positive in 11/41 (26.8%) of 
41 EBER positive PBL cases (Figure 3.4C), while the remaining 30/41 (73.2%) were negative 




Figure 3.4: EBNA1 immunohistochemical staining in control and PBL cases. A. Positive control 
showing nuclear staining in the EBV positive NPC cells.  (20x mag) B. Negative control (20x 
mag). C. EBNA1 positive PBL case 25 (10x mag). D. EBNA1 negative PBL case 2 (20x mag). 
 
3.4.4 EBNA2 
EBV positive NPC tissue served as the positive control and showed a DAB staining reaction in 
the nuclei of the tumour cells (Figure 3.5A). there was no cytoplasmic or non-specific 
background staining in any of the slides processed including the negative control (Figure 3.5B). 
This staining pattern was consistent with the manufacturer specification. All 41 cases were 





Figure 3.5: EBNA2 immunohistochemical staining in control and PBL cases. A. Positive control 
showing nuclear staining in the EBV positive NPC cells. (20x mag) B. Negative control (20x mag). 
C. EBNA2 negative PBL case 2 (20x mag). 
 
3.4.5 LMP1 
EBV positive NPC tissue served as the positive control and showed strong membranous and 
cytoplasmic DAB staining reaction in the tumour cells (Figure 3.6A). There was no nuclear or 
other background staining present in any of the slides processed including thenegative control 
(Figure 3.6B). This staining pattern was consistent with the manufacturer specification. Of the 
41 cases, 4/41 (9.8%) were positive for LMP1 (Figure 3.6C) and the remaining 37/41 (90.2%) 





Figure 3.6: LMP1 immunohistochemical staining in control and PBL cases. A. Positive control 
showing staining in the cytoplasm and cell membrane of the EBV positive NPC cells (20x mag). 
B. Negative control. C. LMP1 positive PBL case 21 (20x mag). D. LMP1 negative PBL case 14 
(20x mag).   
 
3.5 EBV latency determination  
The expression of the latency proteins (EBNA1, EBNA2 and LMP1) and EBER was then used to 
determine the EBV latency type in each case. Latency 0 was observed in 29/41 (70.7%) of PBL 
cases (Figure 3.7) where only EBER was positive.  Latency 1 was observed in 8/41 (19.5%) cases 
(Figure 3.8) where EBER and EBNA1 were expressed. Lastly, latency 2 (Figure 3.9) was observed 
in 4/41 (9.8%) cases where EBER/EBNA1/LMP1 or EBER/LMP1 was expressed. Table 3.2 




Figure 3.7: PBL case 5 showing EBV latency 0.  A. H&E (20x mag). B. EBER positive (20x mag). 




Figure 3.8: PBL case 34 showing EBV latency 1.  A. H&E (20x mag). B. EBER positive (20x mag). 




Figure 3.9: PBL case 35 showing EBV latency 2.  A. H&E (20x mag). B. EBER positive (20x mag). 
C. EBNA1 positive (20x mag). D. EBNA2 negative (20x mag). E. LMP1 positive (20x mag).   
 
Table 3.2: EBV study summary 
EBV parameters Measured values  Obtained values 
EBV status Positive  41 (83.7%) 
Negative  8 (16.3%) 
EBNA1 Positive 11 (26.8%) 
Negative 30 (73.2%) 
EBNA2 Positive 0 (0%) 
Negative  41 (100%) 
LMP1 Positive 4 (9.8%) 
Negative  37 (90.2%) 
Latency  0 29 (70.7%) 
1 8 (19.5%) 
2 4 (9.8%) 
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3.6 MYC FISH 
MYC FISH was performed on all 49 PBL cases using a MYC dual colour break apart probe (BAP). 
To verify the probe, a DLBCL with a MYC translocation served as the positive control (Figure 
3.10A) while a reactive lymph node served as the negative control (Figure 3.10B). The signal 
patterns observed in the controls were consistent with expected results.  
 
 
Figure 3.10: Photomicrographs showing MYC FISH controls. A. Translocated MYC FISH positive 
control showing one yellow or fused orange/green signal and one separate orange and green 
signal in the tumour cell nuclei (white arrow). B. Intact MYC FISH negative control showing two 
yellow or fused orange/green signals (white arrow). 
 
Of the cases tested, 30/49 (61.2%) yielded a result.  In 11/30 (36.7%) cases the MYC gene was 
intact (Figure 3.11B). MYC translocation was observed in 8/30 (26.7%) (Figure 3.12B), while 
combined copy number variations were identified in 11/30 (36.7%) cases. Copy number 
variations consist of 10/11 (90.0%) cases showing a MYC gain (Figure 3.13B) and 1/10 (10.0%) 
case showing MYC amplification (Figure 3.13D).  Table 3.3 provides detailed information of the 




Figure 3.11: Photomicrographs showing comparative H&E and corresponding MYC FISH on 




Figure 3.12: Photomicrographs showing comparative H&E and corresponding MYC FISH result 
of case 9.  A. H&E (20x mag). B. Translocated MYC showing one yellow or fused orange/green 







Figure 3.13: Photomicrographs of comparative H&E stain and MYC copy number variation MYC 
results for case 17 (gain, A and B) and case 44 (amplified, C and D). A. H&E stain. B. MYC gain 
showing 3 yellow or fused orange/green signals C. H&E stain. D. MYC amplification showing >4 
yellow or fused orange/green signals in one PBL case. 
 
Table 3.3: Detailed results of MYC study 
MYC gene status Measured values Obtained values 
Number=49 Translocation 8 (16.3%) 
Gain 10 (20.4%) 
Amplification  1 (2.0%) 
Intact 11 (22.4%) 




3.7 Statistical analysis 
Due to the nature of the data that was obtained from this study, particularly with regards the 
small numbers of both EBV and HIV negative cases as well as dichotomous input variables, a 
detailed statistical analysis and “p” value determination and interpretation was only performed 
on certain data. Where applicable, the MYC results for translocation and copy number variation 
were combined as MYC aberration. Statistical analysis on EBNA1 and MYC showed that among 
EBNA1 positive cases (n=10), MYC was intact in 3, and showed aberrations in 7 cases (p = 0.402, 
Fisher's exact test). 
 
3.8 Interesting observations 
Thirty-seven cases showed HIV/EBV coinfection, 7 cases were positive for HIV only, 2 cases 
were positive for EBV only, and 1 case was negative for both viruses. In HIV/EBV coinfection 
cases, 27 were latency 0, 6 were latency 1 and 4 were latency 2. In HIV/EBV coinfection cases 
(n=21), MYC was intact in 9 cases, translocated in 5 and showed copy number variations in 7 
cases. In HIV positive, EBV negative cases (n=7), MYC was intact in 1, translocated in 4 and 










PBL is a rare aggressive high-grade B-cell NHL, with a very poor outcome and thought to 
account for about 2.6% of AIDS-related lymphomas.  SA is recognised as having the highest 
number of people living with HIV and AIDS. This ultimately results in a high incidence of AIDS 
related diseases, particularly PBL (Boy et al., 2011, Boy et al., 2010). A better understanding of 
PBL, particularly with regards to the role of EBV and MYC in its pathogenesis, would potentially 
allow for better treatment strategies for patients.  
 
Patient clinical characteristics 
Age and gender 
The median age in this study was 39 years, where 81.6% of the patients were between the 
ages of 30 and 49 years. PBL occurs mainly in adults with HIV infection or age related 
immunosenescence, with cases of paediatric PBL rarely being reported (Vaubell et al., 2014, 
Campo et al., 2017). The median age may be affected by HIV infection, where one study found 
that in HIV positive patients the age dropped from 50 to 38 years (Harmon and Smith, 2016), 
which is very much in keeping with what we observed in our predominantly HIV positive cohort. 
In our study the youngest adult patient was 24 years old. GSH does not have a paediatric 
department and as such paediatric cases have been excluded from this study.  
 
Patient immune status 
Our study revealed that 89.9% of patients were HIV positive, three were HIV negative, and 
4.1% had unknown HIV status. One of the unknown cases was a post-transplant patient. PBL 
occurs in immunocompetent, post-transplant and immunocompromised patients, and given 
the high incidence of HIV and AIDS in SA, this may contribute to the increase in cases of 
aggressive lymphomas such as PBL (Campo et al., 2017, Boy et al., 2011). The current setting 
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of HIV/AIDS epidemic in SA has also seen an increase in HNL, where PBL was identified as the 
most common histological subtype (Alli and Meer, 2017).  
  
Site involvement 
In this study, 75.5% of the cases were extranodal, and 24.5% were nodal. Of the extranodal 
cases, more than half (54.1%) originated from the upper aerodigestive tract, which included 
sites such as the oral cavity, maxilla and mandible. PBL presents mainly as an extranodal 
disease, and was originally described in the oral cavity by Delecluse et al., in 1997 in a cohort 
of 16 HIV positive patients (Delecluse et al., 1997, Campo et al., 2017). Extranodal involvement 
may be as high as 90% in reported PBL cases, with only about 10% reported in lymph nodes 
(Campo et al., 2017, Rafaniello Raviele et al., 2009). In post-transplant patients however, lymph 
node involvement was found to increase to 30% (Campo et al., 2017). In our study we observed 
an usually higher nodal involvement of 24.5%, which may possibly be attributed to case 
selection criteria. These criteria allowed for the inclusion of only cases with adequate, well 
preserved tissue. In the lymph node cases, the tissue was considerably larger, well preserved, 
and had more residual tissue left over when compared to the smaller biopsy fragments.  
Another factor that should also be considered is that we did not know the PBL disease 
progression status in our cohort. We were therefore unable to determine if our samples were 
from primary or secondary tumour site involvement.  
 
Pathogenesis  
Overall, the pathogenesis of PBL remains poorly understood and it may be difficult to 
distinguish from other neoplasms with plasmablastic morphology such as PEL and PCM. PBL is  
thought to occur post germinal centre, where the antigen activated B-cells developed into 
plasma cells after undergoing somatic hypermutation and class switch recombination (Castillo 
and Reagan, 2011). The development of PBL is likely dependant on various factors such as 
immunodeficiency (HIV infection), coinfection by oncogenic viruses such as EBV and molecular 





In our study, all the EBV negative and a random selection of EBV positive cases showed no ALK 
staining patterns. PBL shares a similar immunophenotypic staining profile as ALK-positive LBCL. 
It was therefore necessary to perform this assay to show that we indeed had a clean cohort of 
PBL cases.   
 
Epstein-Barr virus 
EBV was first identified as a human tumour virus more than 50 years ago. It is one of 7 known 
oncogenic viruses and is responsible for more than 1.8% of cancer cases worldwide each year. 
These cancers include BL, gastric carcinoma, NPC and PBL (Dawson et al., 2012). EBV infection 
of tumour cells is found in almost all cases of endemic BL (Aguilar et al., 2017).  EBV is the most 
common viral infection in humans and after initial infection, persists as a lifelong latent 
infection (Young et al., 2016).  More than 90% of the population is infected with EBV by the 
age of 40 years (Münz, 2016). EBV positive infection was described in up to 80% of HIV positive 
PBL cases and in approximately 50% of HIV negative cases (Lopez and Abrisqueta, 2018). 
However, not everyone infected by EBV goes on to develop cancers, as the human body’s 
immune response is crucial in preventing this. It appears to be that in PBL where EBV and HIV 
are involved, EBV is the initial viral infector, which then goes into latency. HIV is a secondary 
viral infector which compromises the body’s immune system, allowing EBV to sporadically 
come out of latency and take advantage of this compromised immunity. This is very similar to 
what is found in endemic BL, where the initial infector is also EBV, and secondary infector is 
plasmodium falciparum, which is also able to compromise the body’s immune system. Again, 
this compromised immunity allows EBV to selectively come out of latency  (Pannone et al., 
2014). In both lymphomas, EBV appears to be an opportunistic infective agent which after 
initial infection hides from the immune system through lack of latent protein expression. It is 
then able to move between latent and lytic reactivation as suitable conditions arise. During this 
“hit and run” latent and lytic infection either initially or later when the immunity is 






EBER ISH was used to determine EBV infection in all our cases where EBV status was not known. 
This resulted in 83.7% cases being EBER positive, and 16.3% being negative. Southern blot 
hybridisation was one of the early methods used for the detection of EBV DNA before the use 
of EBER ISH since 1990 (Wu et al., 1990). At GSH, prior to the implementation of EBER ISH, 
LMP1 IHC was the method of choice. EBER ISH was later identified as a more accurate, reliable 
and specific test for the presence of EBER viral transcripts in the nucleus of tumour cells 
infected by EBV. EBER ISH positive staining of non-tumour cells should however not be included 
in the scoring process. Despite the great benefits of choosing EBER ISH as a method of EBV 
detection, when compared with EBV DNA quantification using qPCR, EBV DNA was found in 
EBER negative cases. It is therefore crucial that great care needs to be taken when interpreting 
EBER ISH results, particularly regarding the location and intensity of positive staining. qPCR 
demonstrates a high sensitivity and may potentially  produce false positives when detecting 
viral DNA in non-malignant cells (Okamoto et al., 2017, Gulley and Tang, 2008).  
 
EBNA1 
EBNA1 was expressed in 26.8% of our cases that were positive for the expression of EBER as 
well. The use of EBNA1 IHC is not commonplace in EBV latency studies, with some researchers 
choosing the more sensitive qPCR method instead. This was brought about by sensitivity issues 
with a certain clone of EBNA1 antibody (clone 2B4) when doing IHC. This subsequently resulted 
in qPCR being used instead, as the methodology was considered to be more sensitive (Gulley 
and Tang, 2008, Ambrosio et al., 2017). In one such study using qPCR , of the cases tested, 
92.3% were EBNA1 positive (Ambrosio et al., 2017). We did not however experience any issues 
with our antibody choice, which was validated using NPC or EBV-positive SMT tissue and 
stained as per expectation. EBNA1, whose main function is that of preservation and 
maintenance of EBV DNA and replication of the virus during cell division, may sporadically be 
expressed (Kliszczewska et al., 2017). EBNA1 is expressed during all EBV latencies except 
latency 0, and with this knowledge we were able to provide a distinction between latency 0 





EBNA2 expression was not detected in any of our cases. These findings compared well to other 
studies where EBNA2 expression was also negative  (Valera et al., 2010, Liu et al., 2012). 
Together with EBV-LP, EBNA2 is the first EBV protein that is expressed soon after B-cell 
infection, and then expressed later in latency 3 (Schlee et al., 2004). The lack of EBNA2 
expression was also confirmed in previous studies by qPCR (Ambrosio et al., 2017). Only one 
study showed 1 EBNA2 positive case using conventional IHC (Morscio et al., 2014).  In our 
study, NPC and EBV-positive SMT were used as the control tissue for the detection of EBNA2 
expression. Both malignancies exhibit EBV latency 3 infection, and as a result showed EBNA2 
positive staining in the tumour tissue as per manufacturers insert (Rezk and Weiss, 2007, Rezk 
et al., 2018).  
 
Although not a contributor to the EBNA2 negative results in our study, EBV positive PBL has 
never been tested before for the possibilities of EBV strain variation or its influence on disease 
progression. EBV type 1 and type 2 strains are determined by variations in the coding regions 
of EBNA2 and EBNA3 family of genes. EBV type 2 strain has been found to be more frequently 
associated with HIV positive patients and has more efficient B-cell transformation properties 
(Santos et al., 2014, Young and Murray, 2003).  
 
LMP1 
In our study 9.8% of the cases were positive for LMP1. LMP1 is expressed only during latency 
2 and 3. LMP1 is reported to have a higher prevalence in immunocompromised patients when 
immune surveillance is absent, but this was however not the case in our study. EBNA2 is 
responsible for the upregulation of LMP1, and may potentially be the reason why LMP1 was 
not expressed in some of our EBV positive PBL (Gulley and Tang, 2008, Niedobitek et al., 1997). 
Both LMP1 and EBNA1 can provide resistance to the effect of P53 related death signals in 
genetically damaged cells and thereby promote lymphomageneses. This is however mostly 
evident in classic HL and NPC, where LMP1 is readily expressed and might not be the case in 





Our study found that 70.7% of the cases showed an EBV latency 0, which was defined in our 
research by the expression of only EBER. Latency 0 is also referred to as true or restricted 
latency and results in a state of complete immune evasion by EBV. It is possible that EBV 
exhibits this reduced latent protein expression in B-cells post GC, when undergoing terminal 
differentiation into plasma cells. This results in the cells not being recognised by the T-cell 
immune response (Price and Luftig, 2015, Rezk et al., 2018). Latency 0 has been reported in 




Our study found 19.5% of the cases showed an EBV latency of 1. Latency 1 was defined in our 
research by the expression of EBER and EBNA1 and is also referred to as a restricted latency 
pattern. Latency 1 is the most frequently reported latency to occur in EBV positive PBL (Valera 
et al., 2010, Ambrosio et al., 2017). The sporadic expression of EBNA1, possibly during cell 
division, provides the distinction between latency 0 and latency 1. In many studies latency 1 
has been determined by using the lack of expression of  EBNA2 and LMP1, with very few using 
EBNA1 in their methodology (Valera et al., 2010, Liu et al., 2012). One could however argue as 
to the relevance of distinguishing between latency 0 and 1. Both are restricted latencies and 
occur post GC when the B-cells are undergoing differentiation into plasma cells, which also 
coincides with the EBV life cycle (Shannon-Lowe and Rickinson, 2019). However, it is important 
as more recent research has identified a more complicated role of EBNA1 in tumourigenesis, 
which would warrant further investigation. The expression of EBNA1 in latency 1 has also been 
investigated as a potential target for therapy against EBV related cancers due to its effect of 
the cells growth-promoting pathways (Wilson et al., 2018).   
 
Latency 2 
Our study found that 9.8% of cases showed and EBV latency of 2. Latency 2 was defined in our 
research by the expression of EBER, EBNA1 and LMP1. In the EBV life cycle, latency 2 is referred 
to as the default latency program and is thought to occur in the GC. Thorley-Lawsone et al., 
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2015 stated that “EBV is B lymphotropic and that its biology closely follows that of normal B-
cells” (Thorley-Lawson, 2015). This may provide evidence of the stepwise latency program 
adopted by EBV after initial infection via tonsillar epithelium, which is followed by an abortive 
lytic or pre-latent state (Price and Luftig, 2015). Following this, a post GC latency 0/1 is 
observed (Rezk et al., 2018). Evidence of this was found in a study by Ambrosio et al., 2017, 
where the authors made use of IHC and qPCR to study the latent and lytic cycles of EBV positive 
PBL.  In their study they found the expression of proteins which characterised latency 2, and 
importantly found evidence of an abortive lytic cycle. Lytic protein expression pattern indicated 
an aborted lytic reactivation, which is thought to contribute to EBV associated neoplasms (Price 
et al., 2017, Ambrosio et al., 2017). We did not however conduct any detailed studies into the 
EBV lytic cycle, but our findings of latency 2 may however provide some evidence of an 
attempted EBV reactivation or a transition period from GC latency 2 to post GC latency 0/1.  
 
Latency 3 
No cases in our study showed an EBV latency 3 pattern, due to the lack of co-expression of 
EBER, EBNA1, EBNA2 and LMP1. Latency 3 is also referred to as the EBV growth program and 
is the most immunogenic of all the latencies. It is characterised by the expression of all EBV 
latent proteins and occurs soon after infection (Kliszczewska et al., 2017). It is evidential that 
all latencies originate from latency 3, and EBV embarks on a latency 3 program soon after lytic 
infection or reactivation (Shannon-Lowe and Rickinson, 2019). As mentioned earlier the EBV 
lytic cycle or reactivation was not investigated in this study, which would make it difficult to 
observe latency 3 in PBL. Literature reports that latency 3 occurs in HIV positive patients as 
well as immunosuppression in posttransplant PBL when there is T-cell immune suppression 
(Castillo et al., 2015, Ambrosio et al., 2017, Price and Luftig, 2015). Latency 3 was not observed 
in our study which included mainly HIV positive cases with one post-transplant patient.  
 
EBV study methodology 
This study made use of standard manual immunohistochemical staining on FFPE tissue, using 
EBNA1, EBNA2 and LMP1 primary antibodies. We made these antibody choices based on which 
proteins are expressed by EBV during the various latencies. The most common available 
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methods of EBV latency determination are ISH for the detection of EBER, automated or manual 
IHC staining using primary monoclonal or polyclonal antibodies, and qPCR using commercially 
available primers. Due to its ease of use, affordability and quick turnaround time, IHC is often 
employed when the case material is FFPE (Rezk et al., 2018, Ambrosio et al., 2017, Wu et al., 
1990). In many earlier studies, EBNA2 and LMP1 were often the antibodies of choice in 
determining EBV latency, as both expressed proteins have recognised oncogenic potential. 
EBNA2 prevents cell death and is critical in EBV related B-cell transformation and is responsible 
for the upregulation of LMP1 (Niedobitek et al., 1997). LMP1 is an oncogene whose primary 
role is inhibiting apoptosis and mimicking CD40 induced signalling pathway (Linke-Serinsöz et 
al., 2017, Liu et al., 2012, Rezk and Weiss, 2007, Valera et al., 2010). Other reasons for these 
antibody choices may be due to antibody availability, or literature stating that latency 3 may 
be found in HIV associated PBL, which may be proven by the expression of EBNA2 (Castillo et 
al., 2015, Bibas and Castillo, 2014). EBV latent proteins do however remain difficult to study 
because of their ability to hide from detection by the body’s immune system, and different 
cells expressing varying stages of latency.  
 
MYC  
The transcription factor MYC regulates the expression of several target genes (Rosenthal and 
Younes, 2017), is associated with apoptosis, lipid synthesis, glucose metabolism and has strong 
oncogenic potential (Karube and Campo, 2015, Ambrosio et al., 2017). MYC, a proto-oncogene 
is frequently activated in human cancers. If MYC is deregulated, and uncontrolled by check-
points such as P53, it could possibly contribute to tumorigenesis by virtue of its ability to 
promote metabolic and proliferation activities (Dang, 2013).  
 
MYC intact 
In our study we found MYC intact in 36.7% of the cases. In normal cell function, MYC expression 
is tightly regulated. MYC may be found in almost all cells in the human body, where its main 
function is the regulation of cell growth. In PBL, MYC status alone does not form part of the 
diagnostic criteria (Castillo et al., 2015, Boy et al., 2011). Our study showed a higher than 
reported intact MYC, and a possible reason for this may relate to a limitation of the probe type 
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that was used. BAP FISH probes are only able to identify translocations and amplifications of 
an assigned region of the MYC gene. The probes are not able to detect other possible MYC 
mutations such as insertions, deletions, frameshifts, and a recently discussed cryptic insertion 
of MYC exons into the IGH locus (Wagener et al., 2019). Salaverria et al., 2013 discussed the 
scattering of MYC and IGH break points which potentially rendered breaks in the MYC gene 
undetectable when using FISH. That study was conducted on BL, so the results should be 
viewed with caution despite the fact that PBL and BL share a common cytogenic abnormality 
(Salaverria et al., 2014). 
 
MYC translocated  
We reported MYC translocations in 26.7% of our cases. This is slightly lower than what was 
found in a study by Valera et al., 2010 using a BAP, where MYC translocations were detected 
in 49% of the PBL cases (Valera et al., 2010). In the present study we found MYC intact more 
than translocated. This finding may warrant further investigation, but MYC translocations alone 
do not cause lymphoma (Ott et al., 2013). MYC translocations, which are commonly found in 
PBL, also occur in other diseases and are often associated with an aggressive progression of 
that disease.  Some studies do however suggest that there may not be a significant difference 
in OS in patients with translocated MYC or not, with MYC rearrangements seen as a late genetic 
alteration acquired during disease progression (Nguyen et al., 2017, Valera et al., 2010). Of 
importance were reported findings that in PBL, there were histological differences in cases 
with MYC translocation as opposed to cases where there was no MYC translocation present 
(Taddesse-Heath et al., 2010). When using FISH to identify MYC translocations, consideration 
should be taken with regards to the location of the break points on chromosome 8, which may 
vary from patient to patient. These variations may be as much as 300kb upstream or 
downstream of the MYC loci and may be missed in FISH cytogenetic studies. It is therefore 
essential that the correct probe with flanking regions is chosen in order to identify these 
translocations (Veronese et al., 1995). As mentioned earlier pertaining to FISH methodology, 
is that the sensitivity of MYC detection may be improved with the use of dual colour dual fusion 
probes. A SA study employed BAP for MYC status screening then dual colour dual fusion probes 
to determine MYC status and possible translocation partner gene. In this study the authors 
reported MYC translocations in 60% of their oral PBL cases. This study was however very 
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homogenous in that all the cases were HIV related oral PBL (Boy et al., 2011). This was unlike 
an earlier study conducted by Valera et al., 2010, where the cases were more heterogenous in 
origin representing various nodal and extranodal sites and reported translocations in 49% of 
their cases (Valera et al., 2010).   
 
MYC copy number variations 
We reported copy number variations in 36.7% of our cases, which consisted of both gains and 
amplification of the MYC gene.  Copy number variations are not uncommon in PBL, with  gains 
reported in up to 30% of the cases, (Valera et al., 2010) and amplifications observed in up to 
23.1% of the cases  (Miao et al., 2019). However, it should be noted that MYC gains or 
amplifications detected by FISH, may also be as a result of an increase in the number of copies 
of chromosome 8 or structural abnormalities of that chromosome.  In the setting of aggressive 
B-cell NHLs such as PBL, it is not clear if MYC gains or amplification have any prognostic 
significance, particularly regarding MYC protein expression. In the present study we did not 
however investigate this possibility. In studies conducted to compare MYC protein expression 
to MYC FISH results, all the cases showed increases in MYC protein expression, but it was not 
restricted to MYC translocation or MYC amplified cases alone (Montes-Moreno et al., 2017, 
Laurent et al., 2016). This and other studies support that MYC protein expression is not a 
surrogate for MYC gene aberrations (Chisholm et al., 2015). More interestingly though it was 
also found that a relationship may exist between mutations in the PRDM1 gene and the 
regulation of MYC. The normal expression of PRDM1/BLIMP1 leads to suppression of MYC 
protein expression, which may be lost when PRDM1 gene is mutated. It was also found that 
the relationship between MYC and PRDM1 does not necessarily affect terminal B-cell 
differentiation into plasma cell but may contribute more to its oncogenicity (Montes-Moreno 
et al., 2017, Valera et al., 2010). 
 
Recently a direct link between EBNA1 and MYC expression was reported to exist, with the 
identification of a mechanism mediated by the glycine alanine repeat region (GAr) of EBNA1. 
The EBNA1 GAr may cause translation stress which may bring about the induction of MYC 
(Wilson et al., 2018). This may provide a possible explanation of the potential relationship 
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between EBNA1 and MYC in our study. We found that EBNA1 was positive in 26.8% cases, with 
most of those showing MYC aberrations consisting of either translocations or copy number 
variations. However, when a detailed statistical analysis was conducted on the full EBNA1 
result, a “p” value equal to 0.402 was obtained. Even though this indicates no significant 
statistical relationship, it may prompt for further study into the possible effect of EBNA1 on 
MYC in PBL. Ambrosio et al., 2017 used qPCR very effectively to confirm EBNA1 expression, 
with results of 92.3% in their EBV infected cases (Ambrosio et al., 2017). The use of a sensitive 
technology such as qPCR may possibly provide a better opportunity for correlation with MYC 
FISH results to see if a relationship exists between these two pathogenic entities.  
 
MYC study methodology 
This study made use of dual colour break apart probes (BAP) for the main reason that MYC 
gene aberrations were of interest, but the translocation partner was not. Dual colour/dual 
fusion probes are employed in FISH where more detailed information regarding gene activity 
is required. In PBL and BL, MYC dual colour/dual fusion probes can detect a translocation 
affecting the MYC gene on chromosome 8 and the IGH gene on chromosome 14. Dual fusion 
probes are more sensitive and have a very low chance of obtaining false-positive results. BAP 
on the other hand are useful in cases where there may be various translocation partners 
associated with a known break-point (Liew et al., 2016). Most studies used one or the other 
probe and rarely use both due to cost implications.  
 
Unsuccessful MYC FISH  
In this study, 38.8% of the cases did not yield a result despite optimising the methodology and 
validating the probe.  The reason for the high failure may be related to tissue conditions. Tissue 
fixation is often not standardised, and there is no assurance that all samples are fixed for the 
optimal time. Areas of haemorrhage may have caused autofluorescence in certain tissue, while 
areas of necrosis possibly lead to high degree of non-specific background staining in others 





Although FISH is considered the gold standard method for MYC investigation, some limitations 
do exist. FISH probes are very expensive. Analysis also requires the use of specialised 
microscopes with the correct emission and excitation filters fitted in order to view the 
fluorescent signal. Furthermore, special cameras and imaging analysis software also contribute 
to this expense. Despite these limitations, FISH remains one of the preferred methods for 
cytogenetic analyses.  
 
HIV/EBV coinfection and other observations 
Even though PBL is a HIV/AIDS associated lymphoma, coinfection with viruses such as EBV 
occur frequently. HIV with EBV coinfection may be found  in over 60% of PBL cases, but the full 
pathogenic effect of this coinfection is not fully understood (Boy et al., 2011). In our study we 
showed an HIV/EBV coinfection of 78.7%. This compares well to the 68.9% obtained by Boy et 
al., 2011, where although the cases lacked homogeneity, it was the only  report to detail 
HIV/EBV coinfection in PBL (Boy et al., 2011). Furthermore, in our coinfected cases, latency 0 
was determined in 73.0% of the cases. Latency 1 and latency 2 were found in a further 16.2% 
and 10.8% of the cases respectively.  Our study reported an unusually higher number of latency 
0 cases in the HIV/EBV coinfection cohort. This prompted the question of how HIV/EBV as a 
coinfection contributed to PBL. There are only a few EBV proteins that are of great importance 
when establishing latency in B-cells. These are EBNA1, EBNA2 and LMP1, which were the 
proteins which we used in our study and are expressed in various latent stages. EBNA1 binds 
EBV genome to the host cell, LMP1 drives B-cell activation and proliferation, while EBNA2 
promotes B-cell activation and replication.  In healthy individuals with functional immunity, 
latently infected B-cells may eventually be eliminated by the immune system. This is not the 
case in patients with compromised immunity such as HIV or post-transplant immune 
suppression, where reactivation of EBV is very possible. This could result in an uncontrolled B-
cell proliferation and a multistep progress towards B-cell lymphoma (Kumar V, 2014). Evidence 
of this reactivation or lytic reactivation has been reported previously (Ambrosio et al., 2014, 
Ambrosio et al., 2017, Price and Luftig, 2015). It is therefore possible in our study that under 
the right HIV immune suppressive conditions, EBV can embark on a brief reactivation cycle, 
before resuming a complete latency again. In the present study, this could account for latency 
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0/1 in the HIV/EBV coinfection PBL cases, where the only difference is the expression of EBNA1 
in latency 1. In the coinfected PBL cases where LMP1 was expressed in latency 2, the oncogenic 
role of LMP1 is already established but this finding possibly gives credence to the notion of the 
step wise latency program by EBV (Price and Luftig, 2015). According to Delecluse et al., 2007, 
EBER is expressed in many HIV/EBV positive PBL cases, but LMP1 is however rarely expressed 
(Delecluse et al., 2007). What is encouraging in our study where LMP1 was expressed in 4 
cases, 2 showed translocations, 1 was intact and 1 did not work.  
 
We however also have one PBL patient that was both HIV and EBV negative but has lung cancer. 
The treatment status for the lung cancer is unknown, but cancer may cause a compromised 
immune system, which may contribute to PBL lymphomagenesis (Gonzalez et al., 2018). In 7 
cases, which again is a small dataset in our study, we observed PBL cases that were HIV positive 
and EBV negative. In this small subset, MYC was intact in 14.3% of the cases, was translocated 
in 28.6% of the case and showed copy number variations in the remaining 57.1% of the cases. 
This is an unusual finding, because MYC rearrangements are more commonly observed in EBV 
positive PBL patients (Valera et al., 2010). It is uncommon that HIV infection alone would result 
in MYC rearrangements or copy number variations PBL. It is therefore clear that further 
investigation with a more representative viral infection status is needed.  
 
The role of EBNA1, particularly in relation to MYC behaviour, requires more elucidation. EBNA1 
is expressed during all latencies except latency 0, and its primary role is to ensure extra 
chromosomal replication of the viral episome during cell division. Delecluse et al., 2007 stated 
that EBNA1 protein detection would be a good alternative to the gold standard of EBER ISH for 
the detection of EBV infection (Delecluse et al., 2007). Only our study and another conducted 
by Ambrosio et al., 2017, used EBNA1 as part of their latency determination. In data extracted 
from the tables provided in their study 92.3% cases were EBV positive, and all were EBNA1 
positive as well, by means of qPCR analysis. In those cases, 61.5% showed MYC translocations 
(Ambrosio et al., 2017).  EBV is recognised as a class one carcinogen by the WHO, and EBNA1, 
which is expressed during all but one EBV latency, is thought to act as an oncoprotein 
(Boudreault et al., 2019, Niedobitek, 1999).  
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Importance of EBV and MYC research in PBL  
There is much ongoing research into EBV-directed therapies, but a major drawback is that 
antiviral agents are not as effective due to EBV’s immune evasion capabilities. A study was 
conducted on the effect of the antiviral drug ganciclovir, with arginine butyrate to induce the 
EBV lytic phase.  By inducing the lytic phase, EBV would be identifiable by the body’s immune 
system, resulting in an immune response. This however showed limited efficacy in EBV 
associated lymphomas (Lopez and Abrisqueta, 2018). Despite MYC translocation being found 
in many PBL cases, the MYC gene does not support a targetable binding domain for possible 
directed therapy (Lopez and Abrisqueta, 2018, Boy et al., 2011). Currently, standard treatment 
and therapy is the only option for PBL patients. As a result, the overall survival (OS) may be as 
low as 15 months, due to a relatively poor overall efficacy of standard treatment and therapy. 
This OS may decrease to about 10 months in HIV positive patients.   
 
Future directions 
An observation in our study which was also found in two others, was that EBNA2 was not 
expressed in the EBV positive PBL cases (Valera et al., 2010, Liu et al., 2012). Only one study 
showed EBNA2 in one case, resulting in a latency 3 infection (Morscio et al., 2014). EBNA2, 
which is only expressed in latency 3, is a transcriptional activator for LMP1 which also targeted 
MYC. In 2019, a study investigated EBNA2 in the two different strains of EBV (strain 1 and 2). 
Variation in the nucleotide sequence of EBNA2 defined EBV strain 1 and 2, which furthermore 
affected the way in which EBNA2 acts on B-cells (Young et al., 2016). EBV type 2 strain tends 
to transform B-cells less efficiently than strain 1. To date, the effect of EBV EBNA2 strain 
variation has not formed part of a detailed study on PBL. The use of sensitive sequencing 
techniques to identify the differences in the nucleotide sequences of EBNA2 would possibly 
allow for a better understanding as to which of these are present in the cases of PBL in this 
study. 
 
Besides a distinction between the restrictive EBV latency 0 and 1, the role of EBNA 1 appears 
to be poorly understood in PBL. Some researchers allude to the possibility of EBNA1 having 
minimal immunological host effect, restricted expression, responsible for viral episomal 
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maintenance and EBV retention in dividing B-cells (Wilson et al., 2018). The effect of EBNA1 on 
the behaviour of MYC also certainly warrants further investigation.  
 
Limitations of the present study 
A lack of adequate and preserved extranodal tissue led to a greater than expected nodal PBL 
representation. Not having more representative HIV and EBV negative PBL cases in our sample 
cohort contributed to an inability to perform a suitable correlation of these two viruses and 
the effect they may have on PBL or MYC status. A MYC protein expression analysis was not 
performed in order to investigate a possible relationship between MYC protein expression and 
MYC gene translocations or MYC copy number variations. Only MYC BA FISH probes were used 
in this study, which would detect almost all translocations in the MYC gene, but the 
translocation partner was not identified. Dual colour dual fusion probes may be used in order 




















We achieved the aim of this study, which was an investigation of Epstein-Barr Virus (EBV) 
latency type and MYC gene status in PBL diagnosed at Groote Schuur Hospital. We 
demonstrated a restricted latency pattern of 0/1 in most of our PBL cases, during which time 
only EBER and or EBNA1 were expressed. With the occurrence of latency 2 in some of the 
cases, we demonstrated a possible step wise latency program that EBV embarks on following 
infection or reactivation. To the best of our knowledge, this was also the first study in a SA 
context to investigate EBV latency patterns in PBL. We were the first in our institution to 
perform MYC FISH on a cohort of PBL and found a higher than cited amount of copy number 
variations. Another finding to come out of this research was a small subset of HIV positive and 
EBV negative PBL cases that showed MYC gene aberrations. This uncommon finding does 
however require further investigation as to another possible effector besides EBV on the MYC 
gene in B-cell lymphomas such as PBL. With these achievements we provided sound 
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Appendix 1 – Reagents and buffers 
A. Immunohistochemistry – manual method 
Bluing solution 
A 5ml volume of ammonia solution (Merck KGaA, Darmstadt, Germany) was added to 
995ml deionised water. The solution was mixed well and stored at RT. 
 
10mM Citric acid buffer solution pH 6 
A 4.2g amount of citric acid (Merck KGaA, Darmstadt, Germany) was added to 1900ml 
of deionised H2O. The solution was mixed well on a desktop mixer and the pH adjusted 
6, using 10M sodium hydroxide.  The mixture was then topped up to 2000ml with 
deionised water. 
 
Tris/EDTA buffer solution (10 mM Tris Base, 1 mM EDTA) pH 9 
A 2.42g amount of Trizma Base and 0.74g of EDTA (Merck KGaA, Darmstadt, Germany) 
was added to 1900ml deionised H2O. The solution was mixed well on a desktop mixer 
and the pH of the solution was adjusted to 9, using 10M sodium hydroxide. The mixture 
was then topped up to 2000ml with deionised water. 
 
3% Hydrogen Peroxide  
A 3ml volume of hydrogen peroxide (Merck KGaA, Darmstadt, Germany) was added to 
97ml deionised H2O and mixed well. 
 
Mayer’s Haematoxylin 
A 50g amount of aluminium sulphate (Alum), 1g of haematoxylin, 0.2g of sodium 
iodate, and 20ml of glacial acetic acid (Merck KGaA, Darmstadt, Germany) was added 
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to deionised H2O and topped up to 1000ml. The solution was mixed well, boiled and 
allowed to cool. The solution was filtered if necessary once it was cooled down.  
 
5% Normal Goat Serum  
A 2.5ml volume of normal goat serum (NGS) (DAKO/Agilent, Santa Clara, CA, USA) was 
added to measuring cylinder and made up to 50ml with PBS. This solution was mixed 
well, aliquoted and stored at -20oC for use later. 
 
Phosphate buffered Saline (PBS) 
Ten phosphate buffered saline (PBS) tablets (Oxoid, Hampshire, England) were 
dissolved in 1000ml of deionised H2O. The solution was mixed well before use. 
 
0.1% Phosphate buffered Saline Tween (PBS tween) 
A 200µl volume of Tween 20 (Merck KGaA, Darmstadt, Germany) was added to 300ml 
of PBS.  
 
3,3′- Diaminobenzidine (DAB) 
Two drops of DAB was added to 2ml of substrate solution. Both solutions were included 
in the Liquid DAB + Substrate Chromogen System (DAKO/Agilent, Santa Clara, CA, USA) 







B Immunohistochemistry – semi-automated method on Ventana XT auto-stainer 
reagents and buffers. 
 
10X EZ Prep solution 
EZ prep solution was used for paraffin removal in both IHC and ISH automated staining 
procedures. Two litres of EZ Prep reagent concentrate was made up to 20 litres using 
distilled water. This was stored on the shelf and decanted into the machine bulk 
container as required.  
 
Reaction buffer concentrate 
Reaction buffer is a Tris based buffer solution which was used to rinse between IHC and 
ISH staining procedures. Two litres of reaction buffer reagent concentrate was made 
up to 20 litres using distilled water.. This solution was stored on the shelf and decanted 
into the machine bulk container as required.  
 
LCS 
Also known as liquid coverslip, this solution was used “as is”, and was available in a 2L 
plastic bottle, prediluted. LCS is a high temperature coverslip solution which was used 
to prevent the aqueous solution from evaporating and the section drying out. This 
allowed for a stable IHC environment.  
 
CC1 
Also known as cell conditioning solution 1, was used “as is” and was available in a 2L 





OptiView DAB IHC Detection Kit 
This kit was used for the semi-automated IHC staining. It contained propriety reagents 
in six 25ml dispensers, which were automatically applied by the analyser. These 
reagents were peroxidase, universal linker, HRP multimer, hydrogen peroxide (H2O2), 
3,3′-Diaminobenzidine (DAB) and copper (copper sulphate).  
 
C In situ hybridisation – automated method on Ventana XT auto-stainer reagents and 
buffers.  
(With the exception of the DAB detection system mentioned above in the semi-
automated IHC staining, certain of the bulk reagents for ISH were the same. Below is 
additional bulk reagents and detection system specifically for ISH) 
 
EBER PROBE 
The Ventana Inform EBER probe that was used was packaged in a 5ml automated 
dispenser. The concentration of the fluorescein labelled probe was 750ng/ml. The 
probe was used as is. 
 
10X SSC 
Sodium chloride sodium citrate buffer (SSC) was used for between step stringency wash 
during ISH. Two litres of 10xSSC reagent concentrate was made up to 10 litres using 
distilled water. The reagent was stored on the shelf and decanted into the machine 
bulk container as required. 
 
CC2 
Also known as cell conditioning solution 2, this solution was used “as is” and was 




ISH IVIEW BLUE DETECTION KIT 
This kit was used for semi-automated ISH staining. It contained propriety reagents in 
six 25ml dispensers, which were automatically applied by the analyser. These reagents 
were anti-fluorescein mouse monoclonal antibody, purified goat anti mouse IgG, 
Streptavidin Alkaline Phosphatase, Enhancer (magnesium chloride solution), NBT (nitro 
blue tetrazolium) and BCIP (5-bromo-4-chloro-3-indolyl phosphate).  
 
Red Counterstain II 
This reagent was a propriety pre-packaged 10ml dispenser containing nuclear fast red 
solution. This reagent was used “as is” and dispensed automatically by the analyser. 
 
ISH Protease 3 
This reagent was a propriety pre-packaged 20ml dispenser containing a casein solution 
with a concentration 0.24 U/ml. This reagent was used “as is” and dispensed 
automatically by the analyser. 
 
D Fluorescence in situ hybridisation (FISH) – manual method 
 
1 M hydrochloric acid (HCl) 
A 91.7ml volume of sterile H20 was added to a graduated measuring cylinder. Using a 
graduated pipette, 8.3ml of concentrated HCl was added to the water.  
 
0.2 N hydrochloric acid (HCl)  




0.01 N hydrochloric acid (HCl)  
A 3ml volume of 0.2N HCl was added to 57ml of sterile H2O. 
 
70% Ethanol 
A 350ml volume of absolute ethanol was added to 150ml of sterile H2O. 
 
85% Ethanol 
A 425ml volume of absolute ethanol was added to 75ml of sterile H2O. 
 
20X SSC (3 M sodium chloride; 0.3 M sodium citrate, pH 5.3) 
A 66g amount of 20X SCC powder was added to 200ml of sterile H2O. The solution was 
mixed well and the pH was adjusted to 5.3 with 1N HCl. The solution was then topped 
up with sterile water to a final volume of 250ml. This solution was stable at RT for 6 
months. 
 
2X SSC/0.3% IGEPAL CA-630  
A 50ml volume of 20X SCC (pH 5.3) was added to 420ml of sterile H2O. The solution was 
mixed thoroughly, and the pH adjusted to 7.25 with 1N NaOH. Thereafter 1.5ml of 
IGEPAL CA-630 was added to the solution and mixed well. The solution was then topped 
up to 500ml with sterile H2O, filtered and was stable at RT for up to 6 months. 
 
Pepsin (10% solution)  
A 500mg amount of pepsin was added to 5ml of sterile H2O. The solution was then 




Pepsin working solution  
A 75µl volume of 10% pepsin solution was added to 30ml of 0.01N HCl. 
 
10M sodium hydroxide (NaOH) 
A 40g amount of sodium hydroxide (Merck KGaA, Darmstadt, Germany) was added to 
a conical flask and topped up to the 100ml mark with deionised H2O. The solution was 
placed on a desktop mixer and allowed to dissolve.  
1M sodium thiocyanate  
A 20.27g amount of NaSCN (Merck KGaA, Darmstadt, Germany) was added to 200ml of 
deionised H2O. The solution was placed on a desktop mixer and mixed until all the dry 
ingredients were dissolved. The magnetic stirrer was removed, and the solution made 
up to 250ml with distilled H2O.  
 
Hybridisation probe preparation 
Table 5.1: Hybridisation probe mix. 
Number of sections 1x 
Hybridisation buffer (µl) 3.5 
Sterile H2O (µl) 1.0 
Probe (µl) 0.5 






APPENDIX 2 – Summary of patient results 
Table 5.2: Summary of all case results in this project.  
Study no. Age Gender Site of biopsy N/EN HIV Status EBV Status EBNA1 EBNA2 LMP1 EBV Latency MYC gene status 
1 62 F Mediastinum EN UNK POS NEG NEG NEG 0 TNS 
2 30 F Tonsil EN POS POS NEG NEG NEG 0 TNS 
3 42 F Oral Cavity EN POS POS NEG NEG NEG 0 Intact 
4 46 M Radius EN POS POS NEG NEG NEG 0 TNS 
5 55 F Leg EN POS POS NEG NEG NEG 0 TNS 
6 38 M Nasal EN POS POS NEG NEG NEG 0 TNS 
7 35 F Anal EN POS POS NEG NEG NEG 0 TNS 
8 35 F Oral Cavity EN POS POS NEG NEG NEG 0 TNS 
9 38 M Anal EN POS POS NEG NEG NEG 0 Translocated 
10 32 M Lymph Node N POS POS NEG NEG NEG 0 TNS 
11 55 M Lymph Node N NEG NEG -  -  -  None TNS 
12 31 F Oral Cavity EN POS POS NEG NEG NEG 0 TNS 
13 35 M Oral Cavity EN POS POS NEG NEG NEG 0 Translocated 
14 37 M Thigh EN UNK POS NEG NEG NEG 0 TNS 
15 37 M Chest EN POS POS NEG NEG NEG 0 TNS 
16 35 F Breast EN POS NEG -  -  -  None Translocated 
17 26 M Nasal EN POS POS NEG NEG NEG 0 Copy number variation, gain 
18 49 F Maxilla EN POS POS NEG NEG NEG 0 TNS 
19 38 F Lymph Node N POS NEG -  -  -  None Copy number variation, gain 
20 42 M Lymph Node N POS NEG -  -  -  None Copy number variation, gain 
21 34 M Small Bowel EN POS POS NEG NEG POS 2 Translocated 
22 24 F Maxilla EN POS POS NEG NEG NEG 0 TNS 
23 41 F Nasal EN POS POS POS NEG POS 2 Intact 
24 24 M Oral Cavity EN POS POS NEG NEG NEG 0 Intact 
25 43 M Oral Cavity EN POS POS POS NEG NEG 1 Copy number variation, gain 
26 32 M Neck EN POS NEG -  -  -  None Copy number variation, gain 
27 63 M Testis EN POS POS NEG NEG NEG 0 Intact 
28 30 F Lymph Node N POS POS NEG NEG NEG 0 Intact 
29 47 M Lymph Node N POS  POS NEG NEG NEG 0 Intact 
30 35 M Anal EN POS NEG -  -  -  None Translocated 
31 40 F Tonsil EN POS POS POS NEG NEG 1 Copy number variation, gain 
32 46 M Lymph Node N POS POS POS NEG NEG 1 Copy number variation, gain 
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Study no. Age Gender Site of biopsy N/EN HIV Status EBV Status EBNA1 EBNA2 LMP1 EBV Latency MYC gene status 
33 36 F Nasal  EN POS POS NEG NEG NEG 0 Copy number variation, gain 
34 40 M Nasal  EN NEG POS POS NEG NEG 1 Intact 
35 58 M Lymph Node N POS POS POS NEG POS 2 TNS 
36 48 M Lymph Node N POS NEG -  -  -  None Intact 
37 42 F Mandible EN POS NEG -  -  -  None Copy number variation, gain 
38 48 F Lymph Node N POS POS NEG NEG NEG 0 TNS 
39 32 M Oral Cavity EN POS POS NEG NEG NEG 0 TNS 
40 35 F Pelvis EN POS POS NEG NEG NEG 0 Copy number variation, gain 
41 40 M Lymph Node N POS POS POS NEG POS 2 Translocated 
42 40 M Anal EN POS POS NEG NEG NEG 0 Intact 
43 40 M Oral Cavity EN POS POS NEG NEG NEG 0 Intact 
44 64 M Lymph Node N POS POS POS NEG NEG 1 Copy number variation, amplification 
45 40 M Maxilla EN NEG POS POS NEG NEG 1 Translocated 
46 49 M Subglottic mass EN POS POS POS NEG NEG 1 Intact 
47 37 M Gastric EN POS POS NEG NEG NEG 0 TNS 
48 39 M Oral Cavity EN POS POS NEG NEG NEG 0 TNS 
49 38 F Buttock EN POS POS POS NEG NEG 1 Translocated 
Key: M=Male, F=Female, EN=Extranodal, N=Nodal, HIV=Human Immunodeficiency Virus, UNK=Unknown, POS=Positive, NEG=Negative, 
EBNA1=Epstein-Barr nuclear antigen 1, EBNA2=Epstein-Barr nuclear antigen 2, LMP1=Latent membrane protein 1, TNS=Tissue not suitable. 
